Document:

Exhibit
10.13

 

TECHNOLOGY ASSIGNMENT

 

THIS TECHNOLOGY ASSIGNMENT
(the “Agreement”) is effective only as of the Effective Time (as defined
herein) and is made by and between AnorMED Corporation (as successor in
interest to AnorMED, Inc.), a company incorporated in Canada (together
with its Affiliates, “AnorMED”) and Callisto Pharmaceuticals, Inc., a company
organized under the laws of Delaware (together with its Affiliates, “Callisto”).  Each of AnorMED and Callisto are a “Party”
and, together the “Parties”.

 

RECITALS

 

A.            Johnson
Matthey Public Limited Company, an English corporation (“JM”), and
SmithKline Beecham Corporation, a Pennsylvania corporation (“SKB”),
entered into a Cooperative Research and Assignment Agreement, dated as of January 11,
1990 (the “Cooperative
Agreement”) for a joint research program regarding the synthesis of
certain non-metal compounds.

 

B.            JM
and AnorMED entered into an Asset Transfer Agreement, dated as of June 28,
1996, whereby JM assigned to AnorMED all of its right, title, and interest in
the Cooperative Agreement, including valuable patent rights, technical data and
information relating to the compound Atiprimod (a/k/a Azaspiranes).

 

C.            By
letter dated November 4, 1996, SKB terminated the Cooperative Agreement
and assigned to AnorMED all of its right, title, and interest in the
Cooperative Agreement, including valuable patent rights, technical data and
information relating to the compound Atiprimod (a/k/a Azaspiranes).

 

D.            Pursuant
to a license agreement by and between AnorMED and Synergy Pharmaceuticals, Inc.
(“Synergy”)
dated as of August 28, 2002, as amended by Amendment No. 1 to License
Agreement dated as of May 23, 2003 and Amendment No. 2 to License
Agreement dated as of July 8, 2004 (the “Original License”), AnorMED licensed to
Synergy certain patent rights related to Atiprimod (a/k/a Azaspiranes) and one
patent application (the “Jointly owned patent application”).

 

E.             Synergy
is now a wholly-owned subsidiary of Callisto.

 

F.             AnorMED
is now a wholly-owned subsidiary of Genzyme Corporation.

 

G.            As
of December 31, 2007, Callisto and AnorMED entered into an Amended and
Restated License Agreement (the “Amended License”) superceding and replacing in
its entirety the Original License.

 

 

H.            The
Parties wish to terminate the Amended License and to transfer and assign to
Callisto all right, title and interest in the patent rights, technical data and
information relating to the compound Atiprimod (a/k/a Azaspiranes), on the
terms and conditions set forth herein.

 

AGREEMENT

 

NOW, THEREFORE, the parties agree as follows:

 

1.             Definitions.  As used herein:

 

“Affiliate” shall mean any company or
other business entity controlled by, controlling or under common control with a
party, control being presumed if there is direct or indirect ownership of at
least thirty-three and one-third percent (33 1/3%) (or, if less, the maximum
permitted by applicable law) of the voting stock, equity or income interest.

 

“Effective Time” shall mean the time at which Genzyme receives the full
amount of the Payment in the account designated in Section 4 hereof.

 

“Patent
Rights” shall mean AnorMED’s interest in all the patents and patent
applications which disclose and claim Atiprimod, or an analog or derivative
thereof, or methods of use or manufacture of any of the foregoing, together
with all divisional, extensions, reissues, substitutions, renewals,
continuations and foreign counterparts thereof (including European
Supplementary Protection Certificates) and patents issuing thereon.  Exhibit A attached hereto is presumed by
the Parties to be a complete and accurate list of the Patent Rights; provided
that AnorMED may, within three (3) business days of the Effective Time,
notify Callisto that a patent or patent application listed on Exhibit A is
incorrectly included in the Patent Rights, and a patent or patent application
will not be deemed excluded from the Patent Rights if it is inadvertently
omitted from Exhibit A.

 

“Product” shall mean any product comprising or incorporating Atiprimod
(a/k/a Azaspiranes) and any analogs or derivatives described in the Patent
Rights ad used for the diagnosis, treatment or prevention of disease in humans

 

“Technical Information” shall mean all trade secrets, technical reports
and data concerning Atiprimod (a/k/a Azaspiranes) and any analogs or
derivatives described in the Patent Rights, or any pharmaceutical composition
based on the foregoing, that are necessary to develop, manufacture, have
manufactured, use or commercialize a Product, including, but not limited to,
preclinical data, toxicological studies, methods of synthesis, assay
information and clinical trial data.

 

“Technology” shall mean Patent Rights and Technical Information.

 

2.             Assignment.

 

(a)           Assignment.  At the Effective Time, and in return for six
hundred fifty thousand dollars ($650,000.00) (the “Payment”) and other consideration the
receipt and sufficiency of 

 

 

which is hereby acknowledged,
AnorMED does hereby transfer, assign, set over, and convey to Callisto, and
Callisto’s successors and assigns, all of AnorMED’s right, title, and interest
in and to (in the United States and all foreign countries) the Technology free
and clear of all liens, mortgages, pledges, security interests, prior
assignments and encumbrances of any kind whatsoever, including without limitation
the rights, if any, to sue or bring other actions for past, present or future
infringement thereof.  AnorMED
acknowledges and agrees that the Technology and all proprietary rights to the
Technology are the sole property of Callisto. 
At Callisto’s request, AnorMED shall execute and deliver to Callisto one
or more separate assignments evidencing the foregoing assignment, in form and
substance reasonably satisfactory to Callisto, for filing with the United
States Patent and Trademark Office and other patent authorities throughout the
world, and perform such other acts as may be reasonably necessary to give
effect to the foregoing assignment.

 

(b)           Files and Records.  To the extent AnorMED, or its predecessor
AnorMED, Inc., has not already done so, upon written request by Callisto,
AnorMED shall use reasonably diligent efforts to search for (and provide to
Callisto if found) any existing files and records pertaining to the Technology,
including without limitation all office actions, drafts, receipts, drawings,
correspondence, disclosures, copies, diagnostic reports, prior art and
analyses.

 

(c)           Patent Maintenance and Enforcement
Responsibilities.  Following the Effective Date, Callisto shall assume and be responsible
for maintaining and enforcing the Patent Rights, including, without limitation,
the right to sue and taking responsibility for any action or proceeding
involving the Patent Rights.  All costs
and expenses relating to the maintenance and enforcement of the Patent Rights incurred
on and after the Effective Date shall be borne solely by Callisto.  Notwithstanding the foregoing, Callisto may
elect not to maintain and enforce the Patent Rights at any time after the
Effective Date.

 

(d)           Assignment
Recordation.  The responsibility and cost of recording the
assignment of Patent Rights shall be borne solely by Callisto.

 

3.             Trademarks and Corporate
Name.
 All trademarks (except the “AnorMED”
and “Genzyme” mark) to be utilized by Callisto with Product are and shall be
shall be owned by Callisto.  To the extent
any such trademark is owned by AnorMED, AnorMED agrees to assign and hereby
assigns its entire right, title and interest in such trademark to Callisto, and
further agrees to execute and deliver to Callisto one or more separate
assignments evidencing the foregoing assignment, in form and substance
reasonably satisfactory to Callisto and perform such other acts as may be
reasonably necessary to give effect to the foregoing assignment. Callisto will
not use or reference AnorMED’s, Genzyme’s or any of their Affiliates’ corporate
name without the prior written consent of AnorMED, which such consent may be
withheld for any reason in AnorMED’s sole discretion, unless required by law in
which case the scope and content of such use or reference will be mutually agreed
to by the parties.

 

4              Payment.
The Payment will be made by wire transfer on or before the close of business on
December 19, 2008 to the following account:

 

 

Beneficiary:  Genzyme Corporation

Account Number
: 037-8388

Swift
Code:  MELNUS3P

ABA/Routing
#:  043000261

Bank
Name:  The Bank of New York Mellon

 

5.             Warranties; Disclaimer.

 

(a)           Representations and
Warranties of the Parties.  Each
party represents and warrants to the other party that (a) it has full
right, power, and authority to enter into this Agreement and to carry out the
provisions hereof and (b) it has all necessary corporate approvals for its
execution, delivery and performance of this Agreement.

 

(b)           Disclaimer.  EXCEPT FOR THE WARRANTIES SET FORTH IN SECTION 5(a),
ANORMED MAKES NO OTHER REPRESENTATIONS OR WARRANTIES WITH RESPECT TO THE PATENT
RIGHTS AND EXPRESSLY DISCLAIMS ANY OTHER WARRANTIES, EXPRESS OR IMPLIED,
INCLUDING, WITHOUT LIMITATION, WARRANTIES OF MERCHANTABILITY, FITNESS FOR A
PARTICULAR PURPOSE, PATENTABILITY AND NONINFRINGEMENT OF INTELLECTUAL PROPERTY
RIGHTS OF OTHER PARTIES.

 

6.             Confidentiality.

 

(a) Confidential
Information.  Except as otherwise
provided in this Article 6, during the term of this Agreement and for a
period of five (5) years thereafter, a party (the “Receiving Party”) shall
keep confidential and not disclose or use (except as contemplated by this
Agreement) any proprietary or confidential information received from the other
party (the “Disclosing Party”), including any exchanged under the Original
License and Amended License, provided that Technical Information conveyed to
Callisto pursuant to this Agreement will be deemed confidential information
owned and disclosed by Callisto irrespective of the manner of its
disclosure.  This restriction shall not
apply to any information of the Disclosing Party to the extent the Receiving
Party can demonstrate such information (a) was already known to the
Receiving Party at the time of disclosure (as may be verified by the recipient’s
contemporaneous written records, and excepting Technical Information conveyed
to Callisto), (b) is or becomes public knowledge through no fault of the
Receiving Party, (c) is received without an obligation of confidentiality
from a third party having the lawful right to disclose same, or (d) was
independently developed or discovered by the Receiving Party without the use of
the information disclosed by the Disclosing Party (as may be verified by the
recipient’s contemporaneous written records, and excepting Technical
Information).

 

(b) Authorized
Disclosure.  A Receiving Party may
disclose information received from the Disclosing Party to the extent such
disclosure is (i) required by law, regulation or court order or (ii) reasonably
necessary, in connection with submissions to regulatory authorities for
purposes of this Agreement, filing or prosecuting patent applications
contemplated under this Agreement, prosecuting or defending litigation,
complying with applicable governmental regulations or conducting preclinical or
clinical trials of Product; provided, however, that in the 

 

 

event of any proposed
disclosure, the Receiving Party will use its reasonable efforts to secure
confidential treatment of the information to be disclosed.

 

(c) Injunctive
Relief.  Receiving Party agrees that
the confidential information of the Disclosing Party constitutes valuable trade
secrets. Receiving Party further agrees that breaches of its confidentiality
and non-disclosure obligations concerning the such confidential information of
the Disclosing Party will create irreparable harm for which monetary damages
would be an inadequate remedy, and that the Disclosing Party may seek and upon
proper proof obtain (from a court with proper jurisdiction) an injunction
(without the posting of a bond or other security) to prevent any actual or
threatened breach of this Agreement, as well as damages for already caused harm
in the event of breach of any obligations herein regarding confidentiality.

 

7.             Indemnification.  Callisto or its Affiliates shall indemnify
and defend and hold AnorMED, its Affiliates and their respective officers,
directors, employees, agents, consultants and contractors and their respective
successors, heirs and assigns (the “Indemnified Parties”) harmless from and
against any claim, action, liability, damage, loss, cost or expense (including
reasonable attorneys’ fees and expenses of litigation) (“Loss”) arising from or
related to (a) Callisto’s activities, actions, or inactions under the
Original License, the Amended License, this Agreement or any subsequent
agreement between Callisto and any third party relating to the Technology, (b) any
practice of the Patent Rights, (c) the development, testing, production,
manufacture, supply, promotion, import, sale or use of any Product or
Technology (or any component thereof) including, but not limited to, any
personal injury or product liability matters, or (d) any material breach
of this Agreement by Callisto, or (e) gross negligence or willful
misconduct on the part of Callisto or any Affiliate or sublicensee or
assignee.  AnorMED shall promptly notify
Callisto of any such claim or action, allow Callisto to control the defense of
such claim or action and render all reasonable assistance to Callisto in
connection with defending such claim or action. 
Callisto shall secure and maintain insurance commensurate with its
obligations under this Section 7 and consistent with the reasonable
standards of the industry with respect to the Product.  Callisto shall provide AnorMED with evidence
of such insurance coverage within ten (10) business days after the date of
this Agreement.

 

8.             Effectiveness
of the Agreement.  The Parties
hereby acknowledge and agree that this Agreement is of no force and effect
prior to the Effective Time.  Further,
the Parties acknowledge and agree that, if the Effective Time does not occur on
or prior to 4pm EST on December 19, 2008, this Agreement shall be null and
void and of no force and effect unless otherwise agreed to by the Parties in a
subsequent writing.

 

9.             Miscellaneous.

 

(a) Entire
Agreement; Modification.  This
Agreement constitutes the entire understanding between the parties hereto with
respect to the subject matter hereof and supersedes and cancels all prior
understandings, obligations, promises and agreements, including under the Original
License and the Amended License. Consistent with the foregoing sentence,
notwithstanding anything in the Amended License to the contrary, AnorMED and
Callisto hereby acknowledge and agree that the Amended License is hereby
terminated as of the date hereof and is of no further force or effect and that
all provisions of the Amended License, including those that 

 

 

expressly or implicitly survive
termination, are hereby superseded by this Agreement effective as of the date
hereof.  No modification or amendment
hereof shall be valid or binding on the parties unless made in writing and duly
executed by the parties.

 

(b) Counterparts.  This Agreement may be executed in two or more
counterparts, each of which shall be deemed an original, but all of which together
shall constitute one and the same instrument.

 

(c)  Notices
and Communications.  Any notice or
any other communication required or permitted to be given to a party pursuant
hereto shall be sufficiently given if delivered personally or by facsimile or
express courier service (expenses prepaid) to the address set forth below:

 

	
  AnorMED:

  	
   

  	
  AnorMED
  Corporation

  
	
   

  	
   

  	
  c/o Genzyme
  Corporation

  
	
   

  	
   

  	
  500 Kendall
  Street, Cambridge, MA 02142

  
	
   

  	
   

  	
  Attn:
  General Counsel

  
	
   

  	
   

  	
   

  
	
  Callisto:

  	
   

  	
  Callisto
  Pharmaceuticals, Inc.

  
	
   

  	
   

  	
  420
  Lexington Avenue, Suite # 1609

  
	
   

  	
   

  	
  New York, NY
  10170

  
	
   

  	
   

  	
  Attn: CEO

  

 

or to such other address as the
party shall designate by written notice given to the other party.  All notices, information, reports and other
communications in connection with this Agreement shall be in English.

 

(d) Governing
Law.  This Agreement shall be
governed by and construed in accordance with the laws of the Commonwealth of
Massachusetts, United States (regardless of its or any other state’s choice of
law provisions).

 

(e) Jurisdiction
and Venue.  To the fullest extent
permitted by applicable law, any action or proceeding relating in any way to
this Agreement may only be brought and enforced in the state or federal courts
located in the City of Boston, State of Massachusetts, United States, to the
extent subject matter jurisdiction exists therefore, and the Parties
irrevocably submit to the jurisdiction of such courts in respect of any such
action or proceeding.  The Parties
irrevocably waive, to the fullest extent permitted by applicable law, any
objection that they may now or hereafter have to the laying of venue of any
such action or proceeding in such courts or any claim that any such action or
proceeding brought in such court has been brought in any inconvenient forum.  Any judgment may be entered in any court
having jurisdiction thereof.

 

(signature page to follow)

 

 

IN WITNESS WHEREOF, the parties have caused this Agreement to be duly
executed on December 19, 2008.

 

 

	
   

  	
  ANORMED INC.

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By:

  	
  /s/ Stephen Mahoney

  
	
   

  	
  Name:

  	
  Stephen Mahoney

  
	
   

  	
  Its:

  	
  Assistant Secretary

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  CALLISTO PHARMACEUTICALS INC.

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  By:

  	
  /s/ Gary S. Jacob

  
	
   

  	
  Name:

  	
  Gary S. Jacob

  
	
   

  	
  Its:

  	
  CEO

  

 

 

EXHIBIT A

 

PATENT RIGHTS

 

	
  1.

  	
   

  	
  Title:

  	
   

  	
  Immunomodulatory Azaspiranes

  
	
   

  	
   

  	
   

  	
   

  	
  Priority Application:   USSN
  712,325      7 June 1991

  

 

	
  Reference No.

  	
   

  	
  Territory

  	
   

  	
  Application No.

  	
   

  	
  Filing Date

  	
   

  	
  Issue Date

  	
   

  	
  Patent No. or

  Publication No.

  
	
  20015.00

  Abandoned

  	
   

  	
  US

  	
   

  	
  07/712,325

  	
   

  	
  7-Jun-91

  	
   

  	
   

  	
   

  	
   

  
	
  20015.01

  Abandoned

  	
   

  	
  US

  	
   

  	
  07/981,147

  	
   

  	
  24-Nov-92

  	
   

  	
   

  	
   

  	
   

  
	
  20015.20

  	
   

  	
  US

  	
   

  	
  08/277,456

  	
   

  	
  19-Jul-94

  	
   

  	
  7-Jan-97

  	
   

  	
  US 5,591,748

  
	
  20015.40

  	
   

  	
  PCT

  	
   

  	
  PCT/US92/04834

  	
   

  	
  5-Jun-92

  	
   

  	
   

  	
   

  	
  WO 92/22294

  
	
  20015.41

  	
   

  	
  EPO

  	
   

  	
  92914312.1

  	
   

  	
  5-Jun-92

  	
   

  	
   

  	
   

  	
   

  
	
  20015.42

  	
   

  	
  Ireland

  	
   

  	
  921,827

  	
   

  	
  1-Jul-92

  	
   

  	
   

  	
   

  	
   

  
	
  20015.43

  	
   

  	
  Japan

  	
   

  	
  500972/1993

  	
   

  	
  5-Jun-92

  	
   

  	
  2-Feb-01

  	
   

  	
  3155277

  
	
  20015.44

  	
   

  	
  S. Korea

  	
   

  	
  93-703765

  	
   

  	
  5-Jun-92

  	
   

  	
  13-Jan-00

  	
   

  	
  251570

  
	
  20015.45

  Abandoned

  	
   

  	
  Mexico

  	
   

  	
  922713

  	
   

  	
  5-Jun-92

  	
   

  	
   

  	
   

  	
   

  
	
  20015.46

  Abandoned

  	
   

  	
  New Zealand

  	
   

  	
  243,029

  	
   

  	
  5-Jun-92

  	
   

  	
  29-Nov-94

  	
   

  	
  243029

  
	
  20015.47

  	
   

  	
  Portugal

  	
   

  	
  100,566

  	
   

  	
  4-Jun-92

  	
   

  	
   

  	
   

  	
   

  
	
  20015.48

  Abandoned

  	
   

  	
  S. Africa

  	
   

  	
  92/4107

  	
   

  	
  5-Jun-92

  	
   

  	
  28-Apr-93

  	
   

  	
   

  

 

	
  2.

  	
   

  	
  Title:

  	
   

  	
  Cytokine Inhibitors

  
	
   

  	
   

  	
  Priority Application:   USSN 657,578      19
  February 1991

  

 

	
  Reference No.

  	
   

  	
  Territory

  	
   

  	
  Application No.

  	
   

  	
  Filing

  Date

  	
   

  	
  Issue

  Date

  	
   

  	
  Patent No. or

  Publication No.

  
	
  20019.00

  Abandoned

  	
   

  	
  US

  	
   

  	
  07/657,578

  	
   

  	
  19-Feb-91

  	
   

  	
   

  	
   

  	
   

  
	
  20019.01 Con

  Abandoned

  	
   

  	
  US

  	
   

  	
  07/887,628

  	
   

  	
  22-May-92

  	
   

  	
   

  	
   

  	
   

  
	
  20019.02 Con 01

  	
   

  	
  US

  	
   

  	
  08/138,178

  	
   

  	
  15-Oct-93

  	
   

  	
  11-Feb-97

  	
   

  	
  US 5,602,166

  
	
  20019.03 Con 02

  	
   

  	
  US

  	
   

  	
  08/779,418

  	
   

  	
  7-Jan-97

  	
   

  	
  4-May-99

  	
   

  	
  US 5,900,430

  
	
  20019.20 CIP 02

  Abandoned

  	
   

  	
  US

  	
   

  	
  08/469,415

  	
   

  	
  6-Jun-95

  	
   

  	
   

  	
   

  	
   

  
	
  20019.40

  	
   

  	
  PCT

  	
   

  	
  PCT/US92/01283

  	
   

  	
  18-Feb-92

  	
   

  	
   

  	
   

  	
  WO 02/14462

  
	
  20019.41

  	
   

  	
  Australia

  	
   

  	
  1463392

  	
   

  	
  18-Feb-92

  	
   

  	
  11-Jul-95

  	
   

  	
  657745

  
	
  20019.42

  	
   

  	
  Canada

  	
   

  	
  2,104,214

  	
   

  	
  18-Feb-92

  	
   

  	
   

  	
   

  	
   

  
	
  20019.43

  	
   

  	
  European Patent Office

  	
   

  	
  929073625

  	
   

  	
  18-Feb-92

  	
   

  	
  17-Nov-99

  	
   

  	
  572537B1

  
	
  20019.44

  	
   

  	
  Ireland

  	
   

  	
  920508

  	
   

  	
  18-Feb-92

  	
   

  	
   

  	
   

  	
   

  
	
  20019.45

  	
   

  	
  Japan

  	
   

  	
  04-507323/1992

  	
   

  	
  18-Feb-92

  	
   

  	
  23-Feb-01

  	
   

  	
  3162071

  
	
  20019.46

  Abandoned

  	
   

  	
  S Korea

  	
   

  	
  93-702468

  	
   

  	
  18-Feb-92

  	
   

  	
   

  	
   

  	
   

  
	
  20019.47

  	
   

  	
  S Africa

  	
   

  	
  92/1120

  	
   

  	
  17-Feb-92

  	
   

  	
  27-Jan-93

  	
   

  	
  199201120

  

 

 

	
  20019.48

  	
   

  	
  Austria

  	
   

  	
  92907362.5

  	
   

  	
  18-Feb-92

  	
   

  	
  17-Nov-99

  	
   

  	
  572537

  
	
  20019.49

  	
   

  	
  Belgium

  	
   

  	
  92907362.5

  	
   

  	
  18-Feb-92

  	
   

  	
  17-Nov-99

  	
   

  	
  572537

  
	
  20019.50

  	
   

  	
  Switzerland/

  Liechtenstein

  	
   

  	
  92907362.5

  	
   

  	
  18-Feb-92

  	
   

  	
  17-Nov-99

  	
   

  	
  572537

  
	
  20019.51

  	
   

  	
  Denmark

  	
   

  	
  92907362.5

  	
   

  	
  18-Feb-92

  	
   

  	
  17-Nov-99

  	
   

  	
  572537

  
	
  20019.52

  	
   

  	
  Spain

  	
   

  	
  92907362.5

  	
   

  	
  18-Feb-92

  	
   

  	
  17-Nov-99

  	
   

  	
  572537

  
	
  20019.53

  	
   

  	
  France

  	
   

  	
  92907362.5

  	
   

  	
  18-Feb-92

  	
   

  	
  17-Nov-99

  	
   

  	
  572537

  
	
  20019.54

  	
   

  	
  Great Britain

  	
   

  	
  92907362.5

  	
   

  	
  18-Feb-92

  	
   

  	
  17-Nov-99

  	
   

  	
  572537

  
	
  20019.55

  	
   

  	
  Greece

  	
   

  	
  92907362.5

  	
   

  	
  18-Feb-92

  	
   

  	
  17-Nov-99

  	
   

  	
  2000400311

  
	
  20019.56

  	
   

  	
  Italy

  	
   

  	
  92907362.5

  	
   

  	
  18-Feb-92

  	
   

  	
  17-Nov-99

  	
   

  	
  572537

  
	
  20019.57

  	
   

  	
  Luxembourg

  	
   

  	
  92907362.5

  	
   

  	
  18-Feb-92

  	
   

  	
  17-Nov-99

  	
   

  	
  572537

  
	
  20019.58

  	
   

  	
  Monaco

  	
   

  	
  92907362.5

  	
   

  	
  18-Feb-92

  	
   

  	
  17-Nov-99

  	
   

  	
  572537

  
	
  20019.59

  	
   

  	
  Netherlands

  	
   

  	
  92907362.5

  	
   

  	
  18-Feb-92

  	
   

  	
  17-Nov-99

  	
   

  	
  572537

  
	
  20019.60

  	
   

  	
  Sweden

  	
   

  	
  92907362.5

  	
   

  	
  18-Feb-92

  	
   

  	
  17-Nov-99

  	
   

  	
  572537

  
	
  20019.61

  	
   

  	
  Germany

  	
   

  	
  92907362.5

  	
   

  	
  18-Feb-92

  	
   

  	
  17-Nov-99

  	
   

  	
  P69230314

  
	
  20019.62

  	
   

  	
  Hong Kong

  	
   

  	
  981133586.6

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  

 

 

	
  3.

  	
   

  	
  Title:

  	
   

  	
  2-[2-(Dimethylamino)ethyl]-8,8-dipropyl-2-azaspiro[4,5]decane
  dimaleate

  
	
   

  	
   

  	
  Priority Application:

  	
  U.S. Provisional 60/016/066

  	
  23 April 1996

  
	
   

  	
   

  	
   

  	
  U.S. Provisional 60/001,134

  	
  13 July 1995

  
							

 

	
  Reference

  	
   

  	
  Territory

  	
   

  	
  Application No.

  	
   

  	
  Filing Date

  	
   

  	
  Issue Date

  	
   

  	
  Patent No.

  
	
  20021.00 (US)

  	
   

  	
   

  	
   

  	
  08/981,929

  	
   

  	
  11-Jul-96

  	
   

  	
  14-Sep-99

  	
   

  	
  US 5,952,365

  

 

	
  4.

  	
   

  	
  Title:

  	
   

  	
  N,N-dimethyl-B,B-dipropyl-2-azasprio
  [4,5]decane-2-propanamine dimalcare

  
	
   

  	
   

  	
  Priority Application

  	
  U.S. provisional 60/001,138

  	
  13 July 1995

  
	
   

  	
   

  	
  Priority Application

  	
  U.S. provisional 60/015,996

  	
  23 April 1996

  
							

 

	
  Reference

  	
   

  	
  Territory

  	
   

  	
  Application No.

  	
   

  	
  Filing Date

  	
   

  	
  Issue Date

  	
   

  	
  Patent No. or

  Publication

  No.

  
	
  20024.00

  	
   

  	
  US

  	
   

  	
  08/981,928

  	
   

  	
  12-Jul-96

  	
   

  	
  17-Aug-99

  	
   

  	
  US 5,939,450

  
	
  20024.40

  	
   

  	
  PCT

  	
   

  	
  PCT/US96/11590

  	
   

  	
  12-Jul-96

  	
   

  	
   

  	
   

  	
  WO 97/02820

  
	
  20024.41

  Abandoned

  	
   

  	
  S Africa

  	
   

  	
  96/5883

  	
   

  	
  11-Jul-96

  	
   

  	
  28-May-97

  	
   

  	
  96/5883

  
	
  20024.42

  Abandoned

  	
   

  	
  EPO

  	
   

  	
  969260769

  	
   

  	
  12-Jul-96

  	
   

  	
   

  	
   

  	
  837678

  
	
  20024.43

  	
   

  	
  Japan

  	
   

  	
  09-505996

  	
   

  	
  12-Jul-96

  	
   

  	
  1 June 01

  	
   

  	
  3195364

  

 

 

	
  5.

  	
   

  	
  Title:

  	
   

  	
  N,N-diethyl-8,8-dipropyl-2-azaspiro [4,5] decane-2-propanamine

  
	
   

  	
   

  	
  Priority Application:

  	
  U.S. provisional 60/001,139

  	
  13 July 1995

  
	
   

  	
   

  	
   

  	
  U.S. provisional 60/016,065

  	
  23 April 1996

  
							

 

	
  Reference No.

  	
   

  	
  Territory

  	
   

  	
  Application

  No.

  	
   

  	
  Filing Date

  	
   

  	
  Issue Date

  	
   

  	
  Patent No. or

  Publication No.

  
	
  20029.00

  	
   

  	
  US

  	
   

  	
  08/679,480

  	
   

  	
  12-Jul-96

  	
   

  	
  28-Apr-98

  	
   

  	
  US 5,744,495

  
	
  20029.40

  Abandoned

  	
   

  	
  Algeria

  	
   

  	
  11296

  	
   

  	
  9-Jul-96

  	
   

  	
   

  	
   

  	
   

  
	
  20029.41

  	
   

  	
  Argentina

  	
   

  	
  960103537

  	
   

  	
  11-Jul-96

  	
   

  	
   

  	
   

  	
   

  
	
  20029.42

  	
   

  	
  Australia

  	
   

  	
  5945596

  	
   

  	
  11-Jul-96

  	
   

  	
  8-Jun-00

  	
   

  	
  716256

  
	
  20029.43

  Abandoned

  	
   

  	
  Barbados

  	
   

  	
  81402

  	
   

  	
  12-Jul-96

  	
   

  	
   

  	
   

  	
   

  
	
  20029.44

  	
   

  	
  Brazil

  	
   

  	
  96019093

  	
   

  	
  3-Jul-96

  	
   

  	
   

  	
   

  	
   

  
	
  20029.45

  	
   

  	
  Bulgaria

  	
   

  	
  100710

  	
   

  	
  8-Jul-96

  	
   

  	
  25-Feb-99

  	
   

  	
  62359

  
	
  20029.46

  	
   

  	
  Canada

  	
   

  	
  2,181,006

  	
   

  	
  11-Jul-96

  	
   

  	
   

  	
   

  	
   

  
	
  20029.47

  	
   

  	
  Chile

  	
   

  	
  123696

  	
   

  	
  12-Jul-96

  	
   

  	
  14-Aug-00

  	
   

  	
  40.657

  
	
  20029.48

  	
   

  	
  China

  	
   

  	
  961108207

  	
   

  	
  12-Jul-96

  	
   

  	
  1-Mar-01

  	
   

  	
  96110820.7

  
	
  20029.49

  Abandoned

  	
   

  	
  Colombia

  	
   

  	
  96036764

  	
   

  	
  12-Jul-96

  	
   

  	
   

  	
   

  	
   

  
	
  20029.50

  	
   

  	
  Czech Rep.

  	
   

  	
  PV 203696

  	
   

  	
  9-Jul-96

  	
   

  	
   

  	
   

  	
   

  
	
  20029.51

  Abandoned

  	
   

  	
  Ecuador

  	
   

  	
  SP 961818

  	
   

  	
  11-Jul-96

  	
   

  	
  21-May-98

  	
   

  	
  P1-981368

  
	
  20029.52

  Abandoned

  	
   

  	
  Egypt

  	
   

  	
  66096

  	
   

  	
  11-Jul-96

  	
   

  	
   

  	
   

  	
   

  
	
  20029.53

  	
   

  	
  Eurasia

  	
   

  	
  199600048

  	
   

  	
  12-Jul-96

  	
   

  	
  3-Dec-97

  	
   

  	
  0 00037

  
	
  20029.54

  	
   

  	
  European Patent Office

  	
   

  	
  962019436

  	
   

  	
  11-Jul-96

  	
   

  	
  18-Mar-98

  	
   

  	
  0 753512

  
	
  20029.55

  	
   

  	
  Hungary

  	
   

  	
  P 9601918

  	
   

  	
  12-Jul-96

  	
   

  	
   

  	
   

  	
   

  
	
  20029.56

  	
   

  	
  India

  	
   

  	
  1557/DEL/96

  	
   

  	
  12-Jul-96

  	
   

  	
   

  	
   

  	
   

  
	
  20029.57

  	
   

  	
  Indonesia

  	
   

  	
  P 961950

  	
   

  	
  8-Jul-96

  	
   

  	
   

  	
   

  	
   

  
	
  20029.58

  Abandoned

  	
   

  	
  Israel

  	
   

  	
  118815

  	
   

  	
  8-Jul-96

  	
   

  	
  29-Sep-00

  	
   

  	
   

  
	
  20029.59

  	
   

  	
  Japan

  	
   

  	
  1830581996

  	
   

  	
  12-Jul-96

  	
   

  	
   

  	
   

  	
   

  
	
  20029.60

  	
   

  	
  S Korea

  	
   

  	
  280161996

  	
   

  	
  11-Jul-96

  	
   

  	
   

  	
   

  	
   

  
	
  20029.61

  	
   

  	
  Malaysia

  	
   

  	
  PI 9602865

  	
   

  	
  11-Jul-96

  	
   

  	
   

  	
   

  	
   

  
	
  20029.62

  	
   

  	
  Mexico

  	
   

  	
  962767

  	
   

  	
  12-Jul-96

  	
   

  	
  29-Sep-00

  	
   

  	
  198843

  
	
  20029.63

  	
   

  	
  New Zealand

  	
   

  	
  286951

  	
   

  	
  8-Jul-96

  	
   

  	
  15-Jun-98

  	
   

  	
  286951

  
	
  20029.64

  Abandoned

  	
   

  	
  Nigeria

  	
   

  	
  15396

  	
   

  	
  10-Jul-96

  	
   

  	
  6-Dec-96

  	
   

  	
  12578

  
	
  20029.65

  	
   

  	
  Norway

  	
   

  	
  962931

  	
   

  	
  12-Jul-96

  	
   

  	
  6-Dec-99

  	
   

  	
  306.672

  
	
  20029.66

  Abandoned

  	
   

  	
  Pakistan

  	
   

  	
  450/96

  	
   

  	
  11-Jul-96

  	
   

  	
  11-Nov-98

  	
   

  	
  135353

  
	
  20029.67

  Abandoned

  	
   

  	
  Peru

  	
   

  	
  52596

  	
   

  	
  12-Jul-96

  	
   

  	
   

  	
   

  	
   

  
	
  20029.68

  	
   

  	
  Philippines

  	
   

  	
  53652

  	
   

  	
  8-Jul-96

  	
   

  	
   

  	
   

  	
   

  
	
  20029.69

  	
   

  	
  Poland

  	
   

  	
  315191

  	
   

  	
  10-Jul-96

  	
   

  	
   

  	
   

  	
   

  
	
  20029.70

  	
   

  	
  Romania

  	
   

  	
  9601426

  	
   

  	
  11-Jul-96

  	
   

  	
   

  	
   

  	
   

  
	
  20029.71

  	
   

  	
  Saudi Arabia

  	
   

  	
  96170188

  	
   

  	
  30-Jul-96

  	
   

  	
   

  	
   

  	
   

  
	
  20029.72

  Abandoned

  	
   

  	
  Singapore

  	
   

  	
  96102355

  	
   

  	
  8-Jul-96

  	
   

  	
  22-Aug-00

  	
   

  	
  43383

  
	
  20029.73

  Abandoned

  	
   

  	
  Slovak Rep.

  	
   

  	
  PV 0 88696

  	
   

  	
  8-Jul-96

  	
   

  	
  18-Jan-01

  	
   

  	
   

  
	
  20029.74

  Abandoned

  	
   

  	
  S Africa

  	
   

  	
  965883

  	
   

  	
  11-Jul-96

  	
   

  	
  26-Mar-97

  	
   

  	
  965883

  

 

 

	
  20029.75

  Abandoned

  	
   

  	
  Sri Lanka

  	
   

  	
  11031

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  20029.76

  	
   

  	
  Taiwan

  	
   

  	
  85108324

  	
   

  	
  10-Jul-96

  	
   

  	
  21-Jan-01

  	
   

  	
  126896

  
	
  20029.77

  Abandoned

  	
   

  	
  Tangiers

  	
   

  	
  1399

  	
   

  	
  12-Jul-96

  	
   

  	
   

  	
   

  	
   

  
	
  20029.78

  	
   

  	
  Thailand

  	
   

  	
  32280

  	
   

  	
  9-Jul-96

  	
   

  	
   

  	
   

  	
   

  
	
  20029.79

  	
   

  	
  Turkey

  	
   

  	
  9600579

  	
   

  	
  12-Jul-96

  	
   

  	
  22-Mar-99

  	
   

  	
  TR 1996 00579 B

  
	
  20029.80

  Abandoned

  	
   

  	
  United Arab Emirates

  	
   

  	
  10796

  	
   

  	
  13-Jul-96

  	
   

  	
   

  	
   

  	
   

  
	
  20029.81

  Abandoned

  	
   

  	
  Ukraine

  	
   

  	
  96072764

  	
   

  	
  9-Jul-96

  	
   

  	
   

  	
   

  	
   

  
	
  20029.82

  Abandoned

  	
   

  	
  Uruguay

  	
   

  	
  24283

  	
   

  	
  15-Jul-96

  	
   

  	
   

  	
   

  	
   

  
	
  20029.83

  	
   

  	
  Venezuela

  	
   

  	
  126096

  	
   

  	
  12-Jul-96

  	
   

  	
   

  	
   

  	
   

  
	
  20029.84

  Abandoned

  	
   

  	
  Vietnam

  	
   

  	
  SC 2696

  	
   

  	
  12-Jul-96

  	
   

  	
  29-Sep-00

  	
   

  	
  1500

  
	
  20029.85

  	
   

  	
  Austria

  	
   

  	
  962019436

  	
   

  	
  11-Jul-96

  	
   

  	
  18-Mar-98

  	
   

  	
  0 753512

  
	
  20029.86

  	
   

  	
  Belgium

  	
   

  	
  962019436

  	
   

  	
  11-Jul-96

  	
   

  	
  18-Mar-98

  	
   

  	
  0 753512

  
	
  20029.87

  	
   

  	
  Denmark

  	
   

  	
  962019436

  	
   

  	
  11-Jul-96

  	
   

  	
  18-Mar-98

  	
   

  	
  0 753512

  
	
  20029.88

  	
   

  	
  Finland

  	
   

  	
  962019436

  	
   

  	
  11-Jul-96

  	
   

  	
  18-Mar-98

  	
   

  	
  0 753512

  
	
  20029.89

  	
   

  	
  France

  	
   

  	
  962019436

  	
   

  	
  11-Jul-96

  	
   

  	
  18-Mar-98

  	
   

  	
  0 753512

  
	
  20029.90

  	
   

  	
  Germany

  	
   

  	
  962019436

  	
   

  	
  11-Jul-96

  	
   

  	
  18-Mar-98

  	
   

  	
  0 753512

  
	
  20029.91

  	
   

  	
  Greece

  	
   

  	
  962019436

  	
   

  	
  11-Jul-96

  	
   

  	
  18-Mar-98

  	
   

  	
  3026998

  
	
  20029.92

  	
   

  	
  Netherlands

  	
   

  	
  962019436

  	
   

  	
  11-Jul-96

  	
   

  	
  18-Mar-98

  	
   

  	
  0 753512

  
	
  20029.93

  	
   

  	
  Ireland

  	
   

  	
  962019436

  	
   

  	
  11-Jul-96

  	
   

  	
  18-Mar-98

  	
   

  	
  0 753512

  
	
  20029.94

  	
   

  	
  Italy

  	
   

  	
  962019436

  	
   

  	
  11-Jul-96

  	
   

  	
  18-Mar-98

  	
   

  	
  0 753512

  
	
  20029.95

  	
   

  	
  Luxembourg

  	
   

  	
  962019436

  	
   

  	
  11-Jul-96

  	
   

  	
  18-Mar-98

  	
   

  	
  0 753512

  
	
  20029.96

  Abandoned

  	
   

  	
  Morocco

  	
   

  	
  24311

  	
   

  	
  12-Jul-96

  	
   

  	
   

  	
   

  	
   

  
	
  20029.97

  	
   

  	
  Portugal

  	
   

  	
  962019436

  	
   

  	
  11-Jul-96

  	
   

  	
  18-Mar-98

  	
   

  	
  0 753512

  
	
  20029.98

  	
   

  	
  Spain

  	
   

  	
  962019436

  	
   

  	
  11-Jul-96

  	
   

  	
  18-Mar-98

  	
   

  	
  0 753512

  
	
  20029.99

  	
   

  	
  Sweden

  	
   

  	
  962019436

  	
   

  	
  11-Jul-96

  	
   

  	
  18-Mar-98

  	
   

  	
  0 753512

  
	
  25029.40

  	
   

  	
  Switzerland

  	
   

  	
  962019436

  	
   

  	
  11-Jul-96

  	
   

  	
  18-Mar-98

  	
   

  	
  0 753512

  
	
  25029.41

  Abandoned

  	
   

  	
  Hong Kong

  	
   

  	
  981107432

  	
   

  	
  18-Sep-98

  	
   

  	
  11-Jun-99

  	
   

  	
  HK1010052

  
	
  25029.42

  	
   

  	
  Great Britain

  	
   

  	
  962019436

  	
   

  	
  11-Jul-96

  	
   

  	
  18-Mar-98

  	
   

  	
  753512

  

 

 

	
  6.

  	
   

  	
  Title       Immunomodulatory
  azaspiranes

  
	
   

  	
   

  	
  Priority Application:       USSN
  101,704       28 September 1987

  

 

	
  Reference
  No.

  	
   

  	
  Territory

  	
   

  	
  Application No.

  	
   

  	
  Filing Date

  	
   

  	
  Issue Date

  	
   

  	
  Patent No. or

  Publication

  No.

  
	
  20031.00

  Abandoned

  	
   

  	
  US

  	
   

  	
  07/101,704

  	
   

  	
  28-Sep-87

  	
   

  	
   

  	
   

  	
   

  
	
  20031.20 CIP

  20031.00

  	
   

  	
  US

  	
   

  	
  07/244,229

  	
   

  	
  13-Sep-88

  	
   

  	
  16-Oct-90

  	
   

  	
  US 4,963,557

  
	
  20031.40

  	
   

  	
  PCT

  	
   

  	
  PCT/US88/03323

  	
   

  	
  27-Sep-88

  	
   

  	
   

  	
   

  	
   

  
	
  20031.41

  Abandoned

  	
   

  	
  Bahamas

  	
   

  	
  930

  	
   

  	
  27-Sep-88

  	
   

  	
  14-Apr-89

  	
   

  	
  930

  
	
  20031.42

  	
   

  	
  Canada

  	
   

  	
  578528

  	
   

  	
  27-Sep-88

  	
   

  	
  26-Apr—93

  	
   

  	
  1313189

  
	
  20031.43

  	
   

  	
  China

  	
   

  	
  881090328

  	
   

  	
  27-Sep-88

  	
   

  	
  21-Jan-96

  	
   

  	
  881090328

  
	
  20031.44

  	
   

  	
  Cyprus

  	
   

  	
  883089146

  	
   

  	
  26-Sep-88

  	
   

  	
  12-Sep-96

  	
   

  	
  1955

  
	
  20031.45

  	
   

  	
  Czech Rep

  	
   

  	
  PV 397091

  	
   

  	
  20-Dec-01

  	
   

  	
   

  	
   

  	
   

  
	
  20031.46

  	
   

  	
  European Patent Office

  	
   

  	
  883089146

  	
   

  	
  26-Sep-88

  	
   

  	
  30-Nov-94

  	
   

  	
  0310321

  
	
  20031.47

  	
   

  	
  Ireland

  	
   

  	
  292988

  	
   

  	
  28-Sep-88

  	
   

  	
  16-Apr-96

  	
   

  	
  67891

  
	
  20031.48

  Abandoned

  	
   

  	
  Israel

  	
   

  	
  87908

  	
   

  	
  25-Sep-88

  	
   

  	
  21-Feb-93

  	
   

  	
  87908

  
	
  20031.49

  Abandoned

  	
   

  	
  Malaysia

  	
   

  	
  8801078

  	
   

  	
  27-Sep-88

  	
   

  	
  30-Jul-94

  	
   

  	
  104932

  
	
  20031.50

  	
   

  	
  Mexico

  	
   

  	
  923765

  	
   

  	
  29-Jun-92

  	
   

  	
  10-May-94

  	
   

  	
  174367

  
	
  20031.51

  	
   

  	
  New Zealand

  	
   

  	
  226354

  	
   

  	
  27-Sep-88

  	
   

  	
  13-Jun-91

  	
   

  	
  226354

  
	
  20031.52

  Abandoned

  	
   

  	
  Pakistan

  	
   

  	
  43988

  	
   

  	
  28-Sep-88

  	
   

  	
  26-Dec-90

  	
   

  	
  131497

  
	
  20031.53

  	
   

  	
  Portugal

  	
   

  	
  88603

  	
   

  	
  27-Sep-88

  	
   

  	
  25-Jun-92

  	
   

  	
  88603

  
	
  20031.54

  Abandoned

  	
   

  	
  Singapore

  	
   

  	
  96914205

  	
   

  	
  26-Sep-88

  	
   

  	
  30-Nov-94

  	
   

  	
  96914205

  
	
  20031.55

  	
   

  	
  Slovakia

  	
   

  	
  397097

  	
   

  	
  20-Dec-91

  	
   

  	
   

  	
   

  	
   

  
	
  20031.56

  Abandoned

  	
   

  	
  S Africa

  	
   

  	
  887266

  	
   

  	
  28-Sep-88

  	
   

  	
  27-Jan-93

  	
   

  	
  887266

  
	
  20031.57

  	
   

  	
  Taiwan

  	
   

  	
  77106657

  	
   

  	
  24-Sep-88

  	
   

  	
  26-Apr-91

  	
   

  	
  43871

  
	
  20031.58

  Abandoned

  	
   

  	
  Zimbabwe

  	
   

  	
  12388

  	
   

  	
  21-Sep-88

  	
   

  	
  7-Apr-89

  	
   

  	
  12388

  
	
  20031.59

  	
   

  	
  Australia

  	
   

  	
  253388

  	
   

  	
  27-Sep-88

  	
   

  	
  1-Jun-92

  	
   

  	
  619780

  
	
  20031.60

  	
   

  	
  Denmark

  	
   

  	
  77090

  	
   

  	
  27-Sep-88

  	
   

  	
  8-May-95

  	
   

  	
  170042

  
	
  20031.61

  	
   

  	
  Finland

  	
   

  	
  901530

  	
   

  	
  27-Sep-88

  	
   

  	
  10-Feb-95

  	
   

  	
  93006

  
	
  20031.62

  Abandoned

  	
   

  	
  Hungary

  	
   

  	
  588988

  	
   

  	
  27-Sep-88

  	
   

  	
  24-Sep-93

  	
   

  	
  208809

  
	
  20031.63

  	
   

  	
  Japan

  	
   

  	
  63508105

  	
   

  	
  27-Sep-88

  	
   

  	
  21-Nov-96

  	
   

  	
  2582888

  
	
  20031.64

  Abandoned

  	
   

  	
  S Korea

  	
   

  	
  899-00907

  	
   

  	
  27-Sep-88

  	
   

  	
  22-Sep-98

  	
   

  	
  166366

  
	
  20031.65

  	
   

  	
  Norway

  	
   

  	
  901392

  	
   

  	
  27-Sep-88

  	
   

  	
  9-Feb-94

  	
   

  	
  173824

  
	
  20031.66

  	
   

  	
  Philippines

  	
   

  	
  37609

  	
   

  	
  13-Sep-88

  	
   

  	
  5-Nov-91

  	
   

  	
  25812

  
	
  20031.67

  Abandoned

  	
   

  	
  Hungary

  	
   

  	
  P/P00121

  	
   

  	
  1-Jul-95

  	
   

  	
   

  	
   

  	
  211325

  
	
  20031.68

  	
   

  	
  Austria

  	
   

  	
  883089146

  	
   

  	
  26-Sep-88

  	
   

  	
  30-Nov-94

  	
   

  	
  0 310321

  
	
  20031.69

  	
   

  	
  Belgium

  	
   

  	
  883089146

  	
   

  	
  26-Sep-88

  	
   

  	
  30-Nov-94

  	
   

  	
  0 310321

  
	
  20031.70

  	
   

  	
  France

  	
   

  	
  883089146

  	
   

  	
  26-Sep-88

  	
   

  	
  30-Nov-94

  	
   

  	
  0 310321

  
	
  20031.71

  	
   

  	
  Germany

  	
   

  	
  883089146

  	
   

  	
  26-Sep-88

  	
   

  	
  30-Nov-94

  	
   

  	
  0 310321

  
	
  20031.72

  	
   

  	
  Great Britain

  	
   

  	
  883089146

  	
   

  	
  26-Sep-88

  	
   

  	
  30-Nov-94

  	
   

  	
  0 310321

  
	
  20031.73

  	
   

  	
  Greece

  	
   

  	
  883089146

  	
   

  	
  26-Sep-88

  	
   

  	
  30-Nov-94

  	
   

  	
  0 310321

  

 

 

	
  20031.74

  	
   

  	
  Italy

  	
   

  	
  883089146

  	
   

  	
  26-Sep-88

  	
   

  	
  30-Nov-94

  	
   

  	
  0 310321

  
	
  20031.75

  	
   

  	
  Luxembourg

  	
   

  	
  883089146

  	
   

  	
  26-Sep-88

  	
   

  	
  30-Nov-94

  	
   

  	
  0 310321

  
	
  20031.76

  	
   

  	
  Netherlands

  	
   

  	
  883089146

  	
   

  	
  26-Sep-88

  	
   

  	
  30-Nov-94

  	
   

  	
  0 310321

  
	
  20031.77

  	
   

  	
  Spain

  	
   

  	
  883089146

  	
   

  	
  26-Sep-88

  	
   

  	
  30-Nov-94

  	
   

  	
  0 310321

  
	
  20031.78

  	
   

  	
  Sweden

  	
   

  	
  883089146

  	
   

  	
  26-Sep-88

  	
   

  	
  30-Nov-94

  	
   

  	
  0 310321

  
	
  20031.79

  Abandoned

  	
   

  	
  Hong Kong

  	
   

  	
  98105430

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  HK 1006274

  

 

 

7.             Psoriasis treatment
using Azaspiranes and a method of immunosuppression, using Azaspiranes in
combination with cyclosporine)

 

Patent No. US 5,981,538

Patent No. US 6,051,59Exhibit 10.14

 

SECURITIES
PURCHASE AND EXCHANGE AGREEMENT

 

SECURITIES PURCHASE AGREEMENT (this “AGREEMENT,” “PURCHASE AGREEMENT,”
or “SECURITIES PURCHASE AGREEMENT”), dated as of
                    
            , by
and among CALLISTO PHARMACEUTICALS, INC.,
a Delaware corporation, (“COMPANY”), and
                                                                                      
(the “BUYER”).

 

WHEREAS:

 

  A.       The
Company and the Buyer are executing and delivering this Agreement in reliance
upon the exemption from securities registration afforded by Rule 506 under
Regulation D (“REGULATION D”) as promulgated by the United States Securities
and Exchange Commission (the “SEC”) under the Securities Act of 1933, as
amended (the “1933 ACT” or the “Securities Act”);

 

  B.       Buyer
and other buyers desire to purchase and the Company desires to issue and sell,
upon the terms and conditions set forth in this Agreement, (i) secured 11%
notes of the Company due April 15, 2010 (the “Notes”) and (ii) to
issue Warrants (as defined in Section 1(b)(iv) in the form described
in this Agreement, to purchase shares of Common Stock of the Company in
exchange for certain outstanding warrants in a private offering.  This offering of the Notes to the Buyers
shall be in the principal amount of up to five hundred thousand ($500,000)
dollars (the “Offering”);

 

  C.       The
terms of the Notes and Warrants are set forth in the Company’s Confidential
Offering Summary dated December 12, 2008 (“Offering Summary”);

 

NOW THEREFORE, the
Company and the Buyer hereby agree as follows:

 

1.       PURCHASE AND SALE OF NOTES
AND WARRANTS.

 

(a) CERTAIN DEFINITIONS.  This Securities Purchase Agreement, the Note, the
Security Agreement, the Warrants, and any other agreements delivered together
with this Agreement or in connection herewith shall be referred to herein as
the “Transaction Documents.”  The Company
and the Buyer mutually agree to the terms of each of the Transaction
Documents.  For purposes hereof:

 

“Buyers” means
the Buyer, and other buyers of Notes and Warrants pursuant to the Offering.

 

“Common Stock
Equivalents” means any securities of the Company or the Subsidiaries which
would entitle the holder thereof to acquire, directly or indirectly, at any
time Common Stock, including without limitation, any debt, preferred stock,
rights, options, warrants or other instrument that is at any time convertible
into or exercisable or exchangeable for, or otherwise entitles the holder
thereof to receive, Common Stock.

 

 

“Person” shall mean an individual, a limited liability
company, a partnership, a joint venture, an exempted company, a corporation, a
trust, an unincorporated organization and a government or any department or
agency thereof.

 

(b) PURCHASE OF NOTES AND WARRANTS.  Subject to the satisfaction or waiver of the terms and conditions of this Agreement, on the Closing Date (as defined below), the Company shall issue and sell to Buyer and Buyer agrees to purchase from the Company the Note in a principal amount equal to the Subscription Amount (as defined in Section 10) and that number of Warrants to purchase a number of shares determined by multiplying the Subscription Amount up to the Pro Rata Amount (set forth on Schedule A) of Buyer by 55.96, plus the number of Warrants to purchase the number of shares determined by multiplying the Subscription Amount accepted by the Company in excess of the Pro Rata amount by 90 (the “Warrant Amount”).  The Buyer acknowledges that the amount of Notes and Warrants purchased may be allocated among the Buyers by the Company, in its sole discretion, in the manner set forth in the Offering Summary.
 

(i)   Form of Note.  The
Note shall be in the form annexed
hereto as EXHIBIT A.

 

(ii)  Form of Warrant  The Warrant shall be in the form annexed
hereto as EXHIBIT
B.

 

(iii) Form Of
Payment.  On
or before the Closing Date (as defined below), (i) Buyer shall pay the
purchase price for the Note and the Warrants to be issued and sold to it at the
Closing (as defined below) (the “PURCHASE PRICE”) by wire transfer of
immediately available funds to the Company, in accordance with the Company’s
written wiring instructions and shall deliver the outstanding warrants for
exchange (“Exchanged Warrants”) duly endorsed for transfer (and cancellation by
the Company) in accordance in the manner described in the Company’s
Confidential Summary dated November 5, 2008 against delivery of duly
executed certificates representing the Note (“Note Certificate”) having an
aggregate initial principal amount (the “Original Principal Amount”) equal to
the Purchase Price and the number of Warrants equal to the Warrant Amount, and (ii) the
Company shall deliver such Note Certificates and Warrants duly executed on
behalf of the Company, to such Buyer, against delivery of such Purchase Price.

 

(iii)  Closing Date.  Subject to the satisfaction or waiver of the terms and conditions of this Agreement, the “Closing” shall occur when subscriber funds representing the aggregate Original Principal Amount of the Note being purchased by the Buyer are transmitted by wire transfer of immediately available funds by Sommer & Schneider LLP, in its capacity as Subscription Agent on Buyer’s behalf to the Company, and the Company’s delivery of the Notes and Warrants to the Subscription Agent. The date of the Closing shall be referred to herein as the “Closing Date.”  The Closing contemplated by this Agreement shall occur on the applicable Closing Date at the offices of the Company, or at such other location as may be agreed to by the parties.  Following the Closing Date, the Subscription Agent will deliver the Notes and Warrants to the Buyer within the later of three business days after receipt of the Exchanged Warrants duly endorsed as aforesaid or the Closing Date.

 

 

(v)  Closing Deliveries. On the Closing Date, the Company will deliver certificates representing the applicable Note and Warrants to the Buyer and the Buyer will deliver the Purchase Price and the Exchanged Warrants to the Company.
 

2.       BUYER’S REPRESENTATIONS AND
WARRANTIES. Buyer represents and warrants to the
Company solely as to such Buyer that:

 

   (a)    INVESTMENT PURPOSE.
As of the date hereof, the Buyer is purchasing the Note and the Warrants and
the shares of Common Stock issuable upon exercise thereof (the “Warrant Shares”
and, collectively with the Note and Warrants and Conversion Shares, the “Securities”)
for its own account and not with a present view towards the public sale or
distribution thereof, except pursuant to sales registered or exempted from
registration under the 1933 Act; PROVIDED, HOWEVER, that by making the
representations herein, the Buyer does not agree to hold any of the Securities
for any minimum or other specific term and reserves the right to dispose of the
Securities at any time in accordance with or pursuant to a registration
statement or an exemption under the 1933 Act and applicable state securities
laws.

 

   (b)    ACCREDITED
INVESTOR STATUS. The Buyer is an “accredited investor” as that term
is defined in Rule 501(a) of Regulation D (an “Accredited Investor”).

 

   (c)    RELIANCE ON EXEMPTIONS. The Buyer
understands that the Securities are being offered and sold to it in reliance
upon specific exemptions from the registration requirements of United States
federal and state securities laws and that the Company is relying upon the
truth and accuracy of, and the Buyer’s compliance with, the representations,
warranties, agreements, acknowledgments and understandings of the Buyer set
forth herein in order to determine the availability of such exemptions and the
eligibility of the Buyer to acquire the Securities.

 

   (d)    INFORMATION. The Buyer and its
advisors, if any, have been furnished with all materials relating to the
business, finances and operations of the Company and materials relating to the
offer and sale of the Securities which have been requested by the Buyer or its
advisors. The Buyer and its advisors, if any, have been afforded the
opportunity to ask questions of the Company. Neither such inquiries nor any
other due diligence investigation conducted by Buyer or any of its advisors or
representatives shall modify, amend or affect Buyer’s right to rely on the
Company’s representations and warranties contained in Section 3 below. The
Buyer understands that its investment in the Securities involves a significant
degree of risk.

 

   (e)    GOVERNMENTAL REVIEW. The Buyer
understands that no United States federal or state agency or any other
government or governmental agency has passed upon or made any recommendation or
endorsement of the Securities.

 

   (f)    TRANSFER OR RE-SALE. The Buyer
understands that (i) the sale or re-sale of the Securities has not been
and is not being registered under the 1933 Act or any applicable state
securities laws, and the Securities may not be transferred or resold unless (a) the
Securities are sold pursuant to an effective registration statement under the
1933 Act, (b) the Buyer shall

 

 

have delivered to the Company
an opinion of counsel (which opinion shall be in form, substance and scope
reasonably satisfactory to counsel to the Company) to the effect that the
Securities to be sold or transferred may be sold or transferred pursuant to an
exemption from such registration, (c) the Securities are sold or
transferred to an “affiliate” (as defined in Rule 144 promulgated under
the 1933 Act (or a successor rule) (“RULE 144”) of the Buyer who agrees to sell
or otherwise transfer the Securities only in accordance with this Section 2(f) and
who is an Accredited Investor, or (d) the Securities are sold pursuant to Rule 144
or Rule 144(k); and (ii) any sale of such Securities made in reliance
on Rule 144 or Rule 144(k) may be made only in accordance with
the terms of said Rule. Notwithstanding the foregoing or anything else
contained herein to the contrary, the Securities may be pledged as collateral
in connection with a BONA FIDE margin account or other lending arrangement.

 

(g)    ORGANIZATION; AUTHORIZATION; ENFORCEMENT.
Buyer is a [natural person / (corporation, limited liability company, trust
duly organized, validly existing and in good standing under the laws of the
jurisdiction in which it is organized]. 
Buyer has all requisite power and authority to enter into and perform
this Agreement and the Security Agreement and to consummate the transactions
contemplated hereby and thereby in accordance with the terms hereof and
thereof.  The execution and delivery of
this Agreement has been duly and validly authorized and no further consent or
authorization of Buyer, or any governing body or security holder of the Buyer,
if the Buyer is not a natural person. This Agreement has been duly executed and
delivered on behalf of the Buyer, and this Agreement constitutes, and upon
execution of the Security Agreement, such agreement will constitute, the legal,
valid and binding agreements of the Buyer enforceable in accordance with their
terms.

 

(h)    KNOWLEDGE AND
EXPERIENCE.  Buyer has such knowledge and experience in
financial and business matters that it is capable of evaluating the merits and
risks of the investment in the Securities.

 

(i)    CERTAIN TRADING ACTIVITIES.
As of the Closing Date the Buyer and its Affiliates have not entered into or
effected any “short sales” (as such term is defined in Rule 3b-3 of the
1934 Act) of the Common Stock or hedging transaction which established a net
short position with respect to the Common Stock.  For the purposes of this Agreement, an “Affiliate” of any person or entity means
any other person or entity directly or indirectly controlling, controlled by or
under direct or indirect common control with such person or entity. Affiliate
includes each subsidiary of the Company.

 

(j)    OWNERSHIP OF EXCHANGED WARRANTS.  As of the Closing
Date the Buyer has the complete and absolute right to transfer the Exchanged
Warrants to the Company for cancellation, free and clear of any, liens,
encumbrances or restrictions on transfer (except restrictions under applicable
state and federal securities law) and all necessary action, corporate or
otherwise, has been taken to transfer good title to the Exchanged Warrants to
the Company for cancellation.

 

3.            REPRESENTATIONS
AND WARRANTIES OF THE COMPANY. The Company represents
and warrants to Buyer that, except as set forth on the Company’s disclosure
schedules or any update thereto prior to the Closing Date:

 

 

(a)      ORGANIZATION AND QUALIFICATION.
The Company and each of its Subsidiaries (as defined below), if any, is a
corporation duly organized, validly existing and in good standing under the
laws of the jurisdiction of their respective incorporation, with full power and
authority (corporate and other) to own, lease, use and operate its properties
and to carry on its business as and where now owned, leased, used, operated and
conducted. SCHEDULE 3(A) sets forth a list of all of the Subsidiaries of
the Company and the jurisdiction in which each is incorporated. The Company and
each of its Subsidiaries is duly qualified as a foreign corporation to do
business and is in good standing in every jurisdiction in which its ownership
or use of property or the nature of the business conducted by it makes such
qualification necessary except where the failure to be so qualified or in good
standing would not have a Material Adverse Effect. “Material Adverse Effect”
means any material adverse effect on (i) the Securities, (ii) the
business, operations, assets, financial condition or prospects of the Company
and its Subsidiaries, if any, taken as a whole, (iii) on the transactions
contemplated hereby or by the agreements or instruments to be entered into in
connection herewith or (iv) the authority or the ability of the Company to
perform its obligation under this Agreement, the Security Agreement, the Note
or the Warrants. “Subsidiaries” means any corporation or other organization,
whether incorporated or unincorporated, in which the Company owns, directly or
indirectly, any equity or other ownership interest.

 

(b)      AUTHORIZATION; ENFORCEMENT.
(i) The Company has all requisite corporate power and authority to enter
into and perform this Agreement, the Security Agreement, the Note and the
Warrants and to consummate the transactions contemplated hereby and thereby and
to issue the Securities, in accordance with the terms hereof and thereof, (ii) the
execution and delivery of this Agreement, the Security Agreement, the Note and
the Warrants by the Company and the consummation by it of the transactions
contemplated hereby and thereby (including without limitation, the issuance of
the Note and the Warrants and the issuance and reservation for issuance of the
Warrant Shares issuable upon exercise of or otherwise pursuant to the Warrants)
have been duly authorized by the Company’s Board of Directors and no further
consent or authorization of the Company, its Board of Directors, or its
stockholders is required, (iii) this Agreement has been duly executed and
delivered by the Company, and (iv) this Agreement constitutes, and upon
execution and delivery by the Company of the Security Agreement, the Note and
the Warrants, each of such agreements and instruments will constitute, a legal,
valid and binding obligation of the Company enforceable against the Company in
accordance with their respective terms.

 

(c)      CAPITALIZATION. The capitalization of the Company is as
described in the Company’s most recent report filed with the Commission.  Except as set forth on SCHEDULE 3(c), the
Company has not issued any capital stock since such filing other than pursuant
to the employee stock option plan. 
Except as disclosed in the Company’s reports filed with the Commission,
issued pursuant to the Company’s stock incentive plan or as a result of the
purchase and sale of the Securities, there are no outstanding options,
warrants, script rights to subscribe to, calls or commitments of any character
whatsoever relating to, or securities, rights or obligations convertible into
or exchangeable for, or giving any Person any right to subscribe for or
acquire, any shares of Common Stock, or contracts, commitments, understandings
or arrangements by which the Company or any Subsidiary is or may become bound
to issue

 

 

additional shares of Common
Stock, or securities or rights convertible or exchangeable into shares of
Common Stock.  All of the outstanding
shares of capital stock of the Company are validly issued, fully paid and non-assessable,
have been issued in compliance with all federal and state securities laws, and
none of such outstanding shares was issued in violation of any preemptive
rights or similar rights to subscribe for or purchase securities.

 

No shares of
capital stock of the Company are subject to preemptive rights or any other
similar rights of the stockholders of the Company or any liens or encumbrances
imposed through the actions or failure to act of the Company. Upon request, the
Company has furnished to the Buyer true and correct copies of the Company’s
Certificate of Incorporation as in effect on the date hereof (“Certificate Of
Incorporation”), the Company’s By-laws, as in effect on the date hereof (the “By-Laws”),
and the terms of all securities convertible into or exercisable for Common
Stock of the Company and the material rights of the holders thereof in respect
thereto. The issuance and sale of the Securities will not obligate the Company
to issue shares of Common Stock or other securities to any Person (other than
the Buyers) and will not result in a right of any holder of Company securities
to adjust the exercise, conversion, exchange or reset price under any of such
securities.  No further approval or
authorization of any stockholder, the Board of Directors of the Company or
others is required for the issuance and sale of the Securities.  There are no stockholders agreements, voting
agreements or other similar agreements with respect to the Company’s capital
stock to which the Company is a party or, to the knowledge of the Company,
between or among any of the Company’s stockholders.

 

(d)      ISSUANCE OF SHARES.
Upon exercise of the Warrants in accordance with their respective terms, and
receipt of the exercise price therefor, the Warrant Shares, along with any
other shares issued pursuant to the terms of the Transaction Documents, will be
validly issued, fully paid and non-assessable, and free from all taxes, liens,
claims and encumbrances and shall not be subject to preemptive rights or other
similar rights of stockholders of the Company and will not impose personal
liability upon the holder thereof.

 

(e)      ACKNOWLEDGMENT OF DILUTION.
The Company understands and acknowledges the potentially dilutive effect to the
Common Stock upon the issuance of the Warrant Shares upon exercise of or otherwise
pursuant to the Warrants. The Company’s directors and executive officers have
studied and fully understand the nature of the Securities being sold hereunder.
The Company further acknowledges that its obligation to issue Warrant Shares
upon exercise of or otherwise pursuant to the Warrants in accordance with this
Agreement and the Warrants is absolute and unconditional regardless of the
dilutive effect that such issuance may have on the ownership interests of other
stockholders of the Company. Taking the foregoing into account, the Company’s
Board of Directors has determined, in its good faith business judgment, that
the issuance of the Securities hereunder and under the Warrants and the
consummation of the transactions contemplated hereby and thereby are in the
best interest of the Company and its stockholders.

 

(f)      NO CONFLICTS.
The execution, delivery and performance of each of the Transaction Documents by
the Company and the consummation by the Company of the transactions
contemplated hereby and thereby (including, without limitation, the issuance
and reservation for issuance of the Warrant Shares) will not (i) conflict
with or result in a violation of

 

 

any provision of the
Certificate of Incorporation or By-laws, (ii) trigger any resets of conversion
or exercise prices in other outstanding convertible securities, warrants or
options of the Company, (iii) trigger the issuance of securities by the
Company to any third party, (iv) violate or conflict with, or result in a
breach of any provision of, or constitute a default (or an event which with
notice or lapse of time or both would become a default) under, or give to
others any rights of termination, amendment, acceleration or cancellation of,
any agreement, indenture, patent, patent license or instrument to which the
Company or any of its Subsidiaries is a party, or (v) result in a
violation of any law, rule, regulation, order, judgment or decree (including
federal and state securities laws and regulations and regulations of any
self-regulatory organizations to which the Company or its securities are
subject) applicable to the Company or any of its Subsidiaries or by which any
property or asset of the Company or any of its Subsidiaries is bound or
affected (except, in the case of clauses (i), (iv) and (v) above, for
such conflicts, defaults, terminations, amendments, accelerations,
cancellations and violations as would not, individually or in the aggregate,
have a Material Adverse Effect). Neither the Company nor any of its
Subsidiaries is in violation of its Certificate of Incorporation, By-laws or
other organizational documents and neither the Company nor any of its
Subsidiaries is in default (and no event has occurred which with notice or
lapse of time or both could put the Company or any of its Subsidiaries in
default) under, and neither the Company nor any of its Subsidiaries has taken
any action or failed to take any action that would give to others any rights of
termination, amendment, acceleration or cancellation of, any agreement, indenture
or instrument to which the Company or any of its Subsidiaries is a party or by
which any property or assets of the Company or any of its Subsidiaries is bound
or affected, except for possible defaults as would not, individually or in the
aggregate, have a Material Adverse Effect. The businesses of the Company and
its Subsidiaries, if any, are not being conducted, and shall not be conducted
so long as a Buyer owns any of the Securities, in violation of any law,
ordinance or regulation of any governmental entity the violation of which would
have a Material Adverse Effect. Except as specifically contemplated by this
Agreement or as required under the 1933 Act and any applicable state securities
laws, the Company is not required to obtain any consent, authorization or order
of, or make any filing or registration with, any court, governmental agency,
regulatory agency, self regulatory organization or stock market or any third
party in order for it to execute, deliver or perform any of its obligations
under this Agreement, the Note or the Warrants in accordance with the terms
hereof or thereof or to issue and sell the Note and Warrants in accordance with
the terms hereof and to issue Warrant Shares upon exercise of or otherwise
pursuant to the Warrants.  All consents,
authorizations, orders, filings and registrations which the Company is required
to obtain pursuant to the preceding sentence have been obtained or effected on
or prior to the date hereof. The Company and its Subsidiaries are unaware of
any facts or circumstances which might give rise to any of the foregoing.

 

(g)      SEC DOCUMENTS; FINANCIAL
STATEMENTS.  The
Company has timely filed all reports, schedules, forms, statements and other
documents required to be filed by it with the SEC pursuant to the reporting
requirements of the Securities Exchange Act of 1934, as amended (the “1934 Act”)
and all exhibits included therein and financial statements and schedules
thereto and documents (other than exhibits to such documents) incorporated by
reference therein, being hereinafter referred to herein as the “SEC Documents”).
For purposes of this agreement, “timely filed” shall mean that the applicable
document was filed (i) by its original due date under the 1934 Act, or, if
a request for an extension was timely filed, (ii) by

 

 

such extended due date.  The
Company has delivered, by reference to the SEC’s website and EDGAR thereunder (www.sec.gov),
or made available to Buyer true and complete copies of the SEC Documents.  As of their respective dates, the SEC Documents
complied in all material respects with the requirements of the 1934 Act and the
rules and regulations of the SEC promulgated thereunder applicable to the
SEC Documents, and none of the SEC Documents, at the time they were filed with
the SEC, contained any untrue statement of a material fact or omitted to state
a material fact required to be stated therein or necessary in order to make the
statements therein, in light of the circumstances under which they were made,
not misleading. None of the statements made in any such SEC Documents is, or
has been, required to be amended or updated under applicable law (except for
such statements as have been amended or updated in subsequent filings prior to
the date hereof). As of their respective dates, the financial statements of the
Company included in the SEC Documents complied as to form in all material
respects with applicable accounting requirements and the published rules and
regulations of the SEC with respect thereto. Such financial statements have
been prepared in accordance with United States generally accepted accounting
principles, consistently applied, during the periods involved (except (i) as
may be otherwise indicated in such financial statements or the notes thereto,
or (ii) in the case of unaudited interim statements, to the extent they
may not include footnotes or may be condensed or summary statements) and fairly
present in all material respects the consolidated financial position of the
Company and its consolidated Subsidiaries as of the dates thereof and the
consolidated results of their operations and cash flows for the periods then
ended (subject, in the case of unaudited statements, to normal year-end audit
adjustments). Except as set forth in the financial statements of the Company
included in the SEC Documents, the Company has no liabilities, contingent or
otherwise, other than (i) liabilities incurred in the ordinary course of
business subsequent to the date of the Company’s most recent 10-Q or 10-K and (ii) obligations
under contracts and commitments incurred in the ordinary course of business and
not required under generally accepted accounting principles to be reflected in
such financial statements, which, individually or in the aggregate, are not
material to the financial condition or operating results of the Company.

 

(h)      ABSENCE OF CERTAIN CHANGES.
Except for losses incurred in the ordinary course of business that have been
publicly disclosed prior to the date hereof or as set forth on SCHEDULE 3(H) hereof,
since the date of the Company’s most recent 10-Q, there has been no material
adverse change and no material adverse development in the assets, liabilities,
business, properties, operations, financial condition, results of operations or
prospects of the Company or any of its Subsidiaries. For purposes of this Section 3(h),
the terms “material adverse change” and “material adverse development” shall
exclude continuing losses that are consistent with the Company’s historical
losses.

 

(i)      ABSENCE OF LITIGATION.  Except as disclosed in SCHEDULE 3(I), to the
knowledge of the Company or any of its Subsidiaries, there is no action, suit,
claim, proceeding, inquiry or investigation before or by any court, public
board, government agency, self-regulatory organization or body pending or, to
the knowledge of the Company or any of its Subsidiaries, threatened against or
affecting the Company or any of its Subsidiaries, or their officers or
directors in their capacity as such. SCHEDULE 3(I) contains a complete
list and summary description of any known pending or threatened proceeding
against or affecting the Company or any of its Subsidiaries, without regard to
whether it, if adversely decided, would

 

 

have a Material Adverse Effect.
The Company and its Subsidiaries are unaware of any facts or circumstances
which might give rise to any of the foregoing.

 

(j)      PATENTS, COPYRIGHTS, ETC.  The Company and each
of its Subsidiaries owns or possesses the requisite licenses or rights to use
all Intellectual Property necessary
to enable it to conduct its business as now operated, including but not limited
to its intellectual property and to the best of the Company’s knowledge, as
presently contemplated to be operated in the future), except for such licenses
or rights the failure of which to own or possess would not, individually or in
the aggregate, have a Material Adverse Effect; there is no claim or action by
any person pertaining to, or proceeding pending, or to the Company’s knowledge
threatened, which challenges the right of the Company or of a Subsidiary with
respect to any Intellectual Property necessary to enable it to conduct its
business as now operated (and, except as otherwise set forth in SCHEDULE 3(J) hereof,
to the best of the Company’s knowledge, as presently contemplated to be operated
in the future), except for actions or claims which, if adversely decided, would
not have a Material Adverse Effect; to the best of the Company’s knowledge, the
Company’s or its Subsidiaries’ current and intended products, services and
processes do not infringe on any Intellectual Property or other rights held by
any person, and the Company is unaware of any facts or circumstances which
might give rise to any of the foregoing. The Company and each of its
Subsidiaries have taken reasonable security measures to protect the secrecy,
confidentiality and value of their Intellectual Property.  The Company has Existing Liens on its
Intellectual Property as detailed in SCHEDULE 3(J) hereof.

 

(k)      NO MATERIALLY ADVERSE CONTRACTS,
ETC. Neither the Company nor any of its Subsidiaries
is subject to any charter, corporate or other legal restriction, or any
judgment, decree, order, rule or regulation which in the judgment of the
Company’s officers has or is reasonably likely in the future to have a Material
Adverse Effect that has not been disclosed in the SEC Documents. Neither the
Company nor any of its Subsidiaries is a party to any contract or agreement
which in the judgment of the Company’s officers has or is reasonably likely to
have a Material Adverse Effect that has not been disclosed in the SEC
Documents.

 

(l)      TAX STATUS.
Except as set forth on SCHEDULE 3(L), the Company and each of its Subsidiaries
has made or filed all federal, state and foreign income and all other tax
returns, reports and declarations required by any jurisdiction to which it is
subject (unless and only to the extent that the Company and each of its
Subsidiaries has set aside on its books provisions reasonably adequate for the
payment of all unpaid and unreported taxes) and has paid all taxes and other
governmental assessments and charges that are material in amount, shown or
determined to be due on such returns, reports and declarations, except those
being contested in good faith and has set aside on its books provisions
reasonably adequate for the payment of all taxes for periods subsequent to the
periods to which such returns, reports or declarations apply. There are no
unpaid taxes in any material amount claimed to be due by the taxing authority
of any jurisdiction, and the officers of the Company know of no basis for any
such claim. The Company has not executed a waiver with respect to the statute
of limitations relating to the assessment or collection of any foreign,
federal, state or local tax. Except as set forth on SCHEDULE 3(L), none of the
Company’s tax returns is presently being audited by any taxing authority.

 

 

(m)      DISCLOSURE.
To the best of the Company’s knowledge, all information relating to or
concerning the Company or any of its Subsidiaries set forth in this Agreement
and provided to the Buyer pursuant to Section 2(d) hereof and
otherwise in connection with the transactions contemplated hereby is true and
correct in all material respects and the Company has not omitted to state any
material fact necessary in order to make the statements made herein or therein,
in light of the circumstances under which they were made, not misleading. No
event or circumstance has occurred or exists with respect to the Company or any
of its Subsidiaries or its or their business, properties, prospects, operations
or financial conditions, which has not been publicly announced or disclosed but
under applicable law, rule or regulation, requires public disclosure or
announcement by the Company (assuming for this purpose that the Company’s reports
filed under the 1934 Act are being incorporated into an effective registration
statement filed by the Company under the 1933 Act).

 

(n)      ACKNOWLEDGMENT REGARDING BUYER’S
PURCHASE OF SECURITIES. The Company acknowledges and
agrees that the Buyer is acting solely in the capacity of arm’s length
purchaser with respect to this Agreement and the transactions contemplated
hereby. The Company further acknowledges that Buyer is not acting as a
financial advisor or fiduciary of the Company (or in any similar capacity) with
respect to this Agreement and the transactions contemplated hereby and that any
statement made by Buyer or any of its respective representatives or agents in
connection with this Agreement and the transactions contemplated hereby is not advice
or a recommendation and is merely incidental to the Buyer’s purchase of the
Securities and has not been relied upon by the Company, its officers or
directors in any way. The Company further represents to Buyer that the Company’s
decision to enter into this Agreement has been based solely on the independent
evaluation of the Company and its representatives.

 

(o)      NO INTEGRATED OFFERING.
Neither the Company, nor any of its affiliates, nor any person acting on its or
their behalf, has directly or indirectly made any offers or sales of any
security or solicited any offers to buy any security under circumstances that
would require registration under the 1933 Act of the issuance of the Securities
to the Buyer. The issuance of the Securities to the Buyer will not be
integrated with any other issuance of the Company’s securities (past, current
or future) for purposes of any stockholder approval provisions applicable to
the Company or its securities.

 

(p)      NO BROKERS.  Other than as set forth on SCHEDULE 3(P), the
Company has taken no action which would give rise to any claim by any person
for brokerage commissions, finder’s fees or similar payments relating to this
Agreement or the transactions contemplated hereby.  The
Company shall indemnify and hold harmless each of Buyer, its employees,
officers, directors, agents, and partners, and their respective Affiliates,
from and against all claims, losses, damages, costs (including the costs of
preparation and attorney’s fees) and expenses suffered in respect of any such
claimed or existing fees.

 

(q)      PERMITS; COMPLIANCE.
The Company and each of its Subsidiaries is in possession of all franchises,
grants, authorizations, licenses, permits, easements, variances, exemptions,
consents, certificates, approvals and orders necessary to own, lease and
operate its properties and to carry on its business as it is now being
conducted (collectively, the “Company

 

 

Permits”), except where the
failure to so possess any such Company Permits would not have a Material Adverse
Effect, and there is no action pending or, to the knowledge of the Company,
threatened regarding suspension or cancellation of any of the Company Permits.
To the best of the Company’s knowledge, neither the Company nor any of its
Subsidiaries is in conflict with, or in default or violation of, any of the
Company Permits, except for any such conflicts, defaults or violations which,
individually or in the aggregate, would not reasonably be expected to have a
Material Adverse Effect.  Since December 31,
2007, neither the Company nor any of its Subsidiaries has received any
notification with respect to possible conflicts, defaults or violations of
applicable laws, except for notices relating to possible conflicts, defaults or
violations, which conflicts, defaults or violations would not have a Material
Adverse Effect.

 

(r)         ENVIRONMENTAL
MATTERS.

 

(i)     Except as set forth in
SCHEDULE 3(r), there are, to the Company’s knowledge, with respect to the
Company or any of its Subsidiaries or any predecessor of the Company, no past
or present violations of Environmental Laws (as defined below), releases of any
material into the environment, actions, activities, circumstances, conditions,
events, incidents, or contractual obligations which may give rise to any common
law environmental liability or any liability under the Comprehensive
Environmental Response, Compensation and Liability Act of 1980 or similar
federal, state, local or foreign laws and neither the Company nor any of its
Subsidiaries has received any notice with respect to any of the foregoing, nor
is any action pending or, to the Company’s knowledge, threatened in connection
with any of the foregoing. The term “Environmental Laws” means all federal,
state, local or foreign laws relating to pollution or protection of human
health or the environment (including, without limitation, ambient air, surface
water, groundwater, land surface or subsurface strata), including, without
limitation, laws relating to emissions, discharges, releases or threatened
releases of chemicals, pollutants contaminants, or toxic or hazardous
substances or wastes (collectively, “Hazardous Materials”) into the
environment, or otherwise relating to the manufacture, processing,
distribution, use, treatment, storage, disposal, transport or handling of
Hazardous Materials, as well as all authorizations, codes, decrees, demands or
demand letters, injunctions, judgments, licenses, notices or notice letters,
orders, permits, plans or regulations issued, entered, promulgated or approved
thereunder.

 

(ii)     Other than those that are or
were stored, used or disposed of in compliance with applicable law, no
Hazardous Materials are contained on or about any real property currently
owned, leased or used by the Company or any of its Subsidiaries, and no
Hazardous Materials were released on or about any real property previously
owned, leased or used by the Company or any of its Subsidiaries during the
period the property was owned, leased or used by the Company or any of its
Subsidiaries, except in the normal course of the Company’s or any of its
Subsidiaries’ business.

 

(iii)     There are no underground
storage tanks on or under any real property owned, leased or used by the
Company or any of its Subsidiaries that are not in compliance with applicable
law.

 

 

(s)           TITLE TO PROPERTY.
Any real property and facilities held under lease by the Company and its
Subsidiaries are held by them under valid, subsisting and enforceable leases
with such exceptions as would not have a Material Adverse Effect.

 

(t)            INSURANCE. The
Company and each of its Subsidiaries are insured by insurers of recognized
financial responsibility against such losses and risks and in such amounts as
management of the Company believes to be prudent and customary in the
businesses in which the Company and its Subsidiaries are engaged. Neither the
Company nor any such Subsidiary has any reason to believe that it will not be
able to renew its existing insurance coverage as and when such coverage expires
or to obtain similar coverage from similar insurers as may be necessary to
continue its business at a cost that would not have a Material Adverse Effect.

 

(u)           INTERNAL ACCOUNTING
CONTROLS. The Company and each of its Subsidiaries maintain a system of
internal accounting controls sufficient, in the judgment of the Company’s board
of directors, to provide reasonable assurance that (i) transactions are
executed in accordance with management’s general or specific authorizations, (ii) transactions
are recorded as necessary to permit preparation of financial statements in
conformity with generally accepted accounting principles and to maintain asset
accountability, (iii) access to assets is permitted only in accordance
with management’s general or specific authorization and (iv) the recorded
accountability for assets is compared with the existing assets at reasonable
intervals and appropriate action is taken with respect to any differences.

 

(v)            FOREIGN CORRUPT
PRACTICES. Neither the Company, nor any of its Subsidiaries, nor any
director, officer, agent, employee or other person acting on behalf of the
Company or any Subsidiary has, in the course of his actions for, or on behalf
of, the Company, used any corporate funds for any unlawful contribution, gift,
entertainment or other unlawful expenses relating to political activity; made
any direct or indirect unlawful payment to any foreign or domestic government
official or employee from corporate funds; violated or is in violation of any
provision of the U.S. Foreign Corrupt Practices Act of 1977; or made any bribe,
rebate, payoff, influence payment, kickback or other unlawful payment to any
foreign or domestic government official or employee.

 

(v)            NO INVESTMENT COMPANY.
The Company is not, and upon the issuance and sale of the Securities as
contemplated by this Agreement will not be an “investment company” required to
be registered under the Investment Company Act of 1940 (an “INVESTMENT COMPANY”).
The Company is not controlled by an Investment Company.

 

(w)           NO MARKET MANIPULATION. The Company has not taken, and will not take, directly or indirectly, any action designed to, or that might reasonably be expected to, cause or result in stabilization or manipulation of the price of the Common Stock of the Company to facilitate the sale or resale of the Securities or affect the price at which the Securities may be issued or resold.
 
(y)           STOP TRANSFER.  The Securities, when issued, will be restricted securities. The Company will not issue any stop transfer order or other order impeding the sale,

 

 

resale or delivery of any of the Securities, except as may be required by any applicable federal or state securities laws and unless contemporaneous notice of such instruction is given to the Buyer.
 
(z)           NO UNDISCLOSED LIABILITIES. The Company has no liabilities or obligations which are material, individually or in the aggregate, other than those incurred in the ordinary course of the Company’s businesses which have been disclosed in the Company’s public filings and which, individually or in the aggregate, would reasonably be expected to have a Material Adverse Effect.
 
(aa)         NO UNDISCLOSED EVENTS OR CIRCUMSTANCES.  Other than events or circumstances which have been disclosed in the Company’s public filings made no less that 48 hours immediately preceding the Closing, no event or circumstance has occurred or exists with respect to the Company or its businesses, properties, operations or financial condition, that, under applicable law, rule or regulation, requires public disclosure or announcement prior to the date hereof by the Company but which has not been so publicly announced or disclosed in the Reports.
 
(bb)         NO DISAGREEMENTS WITH ACCOUNTANTS AND LAWYERS. There are no disagreements of any kind presently existing, or reasonably anticipated by the Company to arise, between the Company and the accountants and lawyers formerly or presently employed by the Company, including but not limited to disputes or conflicts over payment owed to such accountants and lawyers.
 

(cc)         TRANSACTIONS
WITH AFFILIATES.  Except as
set forth in the SEC Documents filed at least 48 hours prior to the Closing
Date and other than the grant of stock options, none of the officers, directors
or employees of the Company or any of its Subsidiaries is presently a party to
any transaction with the Company or any of its Subsidiaries (other than for
ordinary course services as employees, officers or directors), including any
contract, agreement or other arrangement providing for the furnishing of
services to or by, providing for rental of real or personal property to or from,
or otherwise requiring payments to or from any such officer, director or
employee or, to the knowledge of the Company or any of its Subsidiaries, any
corporation, partnership, trust or other entity in which any such officer,
director, or employee has a substantial interest or is an officer, director,
trustee or partner.

 

4.     COVENANTS.

 

(a)           BEST EFFORTS. The
parties shall use their best efforts to satisfy timely each of the conditions
described in Sections 7 and 8 of this Agreement.

 

(b)           FORM D; BLUE SKY
LAWS. The Company agrees to file a Form D with respect to the
Securities as required under Regulation D and to provide a copy thereof to
Buyer promptly after such filing. The Company shall, on or before the Closing
Date, take such action as the Company shall reasonably determine is necessary
to qualify the Securities for sale to the Buyer at the Closing pursuant to this
Agreement under applicable securities or “blue sky”

 

 

laws of the states of the United States (or to obtain an exemption from
such qualification), and shall provide evidence of any such action so taken to
Buyer on or prior to the Closing Date.

 

(c)           REPORTING STATUS.
The Company’s Common Stock is registered under Section 12(g) of the
1934 Act. So long as any Buyer beneficially owns any of the Securities, the
Company shall timely file all reports required to be filed with the SEC
pursuant to the 1934 Act (“1934 Act Filings”), and the Company shall not
terminate its status as an issuer required to file reports under the 1934 Act
even if the 1934 Act or the rules and regulations thereunder would permit
such termination.

 

(d)           USE OF PROCEEDS.
The Company shall use the proceeds from the sale of the Note and the Warrants
for general corporate purposes.

 

(e)           SECURITIES
LAWS DISCLOSURE; PUBLICITY.  The Company shall, by 5:30 p.m. New York Time
on the fourth business day following the Closing Date, issue a Current Report
on Form 8-K, disclosing the material terms of the transactions
contemplated hereby and including the Transaction Documents as exhibits
thereto.  No Buyer shall issue any such
press release or otherwise make any such public statement without the prior
consent of the Company, which consent shall not unreasonably be withheld or
delayed, except if such disclosure is required by law, in which case the
disclosing party shall promptly provide the other party with prior notice of
such public statement or communication. 
Notwithstanding the foregoing, the Company shall not publicly disclose
the name of any Buyer, or include the name of any Buyer in any filing with the
Commission or any regulatory agency or any market or exchange, without the
prior written consent of such Buyer, except (i) as required by federal
securities law in connection with (A) any registration statement
contemplated by the Registration Rights Agreement and (B) the filing of
final Transaction Documents (including signature pages thereto) with the
SEC  and (ii) to the extent such
disclosure is required by law or regulations of the Principal Market, in which
case the Company shall provide the Buyers with prior notice of such disclosure
permitted under this subclause (ii).

 

(g)           FINANCIAL INFORMATION.
The Company agrees to send, or make available via public filings on the
internet, the following reports to Buyer until Buyer transfers, assigns, or
sells all of the Securities: (i) within ten (10) days after the
filing with the SEC, a copy of its Annual Report on Form 10-K, its
Quarterly Reports on Form 10-Q and any Current Reports on Form 8-K; (ii) within
one (1) day after release, copies of all press releases issued by the
Company or any of its Subsidiaries; and (iii) contemporaneously with the
making available or giving to the stockholders of the Company, copies of any
notices or other information the Company makes available or gives to such
stockholders.

 

(h)           CORPORATE EXISTENCE.
So long as a Buyer beneficially owns any portion of the Note or Warrants, the
Company shall maintain its corporate existence in good standing and remain a “Reporting
Issuer” (defined as a Company which files periodic reports under the Exchange
Act)..

 

(i)            NO INTEGRATION.
The Company shall not make any offers or sales of any security (other than the
Securities) under circumstances that would require registration of the

 

 

Securities being offered or sold hereunder under the 1933 Act or cause
the offering of the Securities to be integrated with any other offering of
securities by the Company for the purpose of any stockholder approval provision
applicable to the Company or its securities.

 

(j)            EQUAL TREATMENT OF BUYERS.  No consideration shall be offered or paid to
any person to amend or consent to a waiver or modification of any provision of
any of the Transaction Agreements unless the same consideration is also offered
to all of the parties to the Transaction Agreements.

 

5. 
SECURED DEBT.  The Borrower hereby represents that there are
no liens or encumbrances on the Collateral (as defined in the Security
Agreement).  The Company agrees that from
the Issue Date of the Notes through the date that all of the Notes have been
paid in full or converted in full (the “Covered Period”), the Company shall not
enter into, create, incur, assume or suffer to exist any mortgage, lien,
pledge, charge, security interest or other encumbrance (collectively, “Liens”)
upon the Collateral other than the Liens contemplated by the Security
Agreement.  Before entering into any
future debt with a third party, the Company shall first obtain a subordination
agreement, satisfactory to Buyer, from the proposed debt holder.

 

6. 
LEGENDS.

 

(a)  The Warrant Shares,
together with any other shares of Common Stock that are issued or issuable
pursuant to the Transaction Documents shall be referred to herein as the “Issued
Common Shares.”  Certificates evidencing
the Issued Common Shares shall not contain any legend restricting the transfer
thereof (including the legend set forth in Section 2(e) of the Note):
(i) while a registration statement (including the Registration Statement)
covering the resale of such security is effective under the Securities Act, or (ii) following
any sale of such Issued Common Shares pursuant to Rule 144, or (iii) if
such Issued Common Shares are eligible for sale under Rule 144(b)(1)(i),
or (iv) if such legend is not required under applicable requirements of
the Securities Act (including judicial interpretations and pronouncements
issued by the staff of the Commission) (collectively, the “Unrestricted
Conditions”).. If the Unrestricted Conditions are met at the time of issuance
of Issued Common Shares, then such Issued Common Shares shall be issued free of
all legends.  The Company agrees that
following such time as the Unrestricted Conditions are met or such legend is
otherwise no longer required under this Section 6(b), it will, no later
than three Trading Days following the delivery by a Buyer to the Company or the
Company’s transfer agent of a certificate representing Issued Common Shares, as
applicable, issued with a restrictive legend (such third Trading Day, the “Legend
Removal Date”), deliver or cause to be delivered to such Buyer a
certificate representing such shares that is free from all restrictive and
other legends.

 

(b)  Each Buyer, severally
and not jointly with the other Buyers, agrees that the removal of the
restrictive legend from certificates representing Securities as set forth in
this Section 6 is predicated upon the Company’s reliance that the Buyer
will sell any Securities pursuant to either the registration requirements of
the Securities Act, including any applicable prospectus delivery requirements,
or an exemption therefrom, and that if Securities are sold 

 

 

pursuant to a Registration Statement, they
will be sold in compliance with the plan of distribution set forth therein.

 

7.             CONDITIONS TO THE
COMPANY’S OBLIGATION TO SELL. The obligation of the Company hereunder to
issue and sell the Note and Warrants to a Buyer at the Closing is subject to
the satisfaction, at or before the Closing Date, of each of the following
conditions thereto, provided that these conditions are for the Company’s sole
benefit and may be waived by the Company at any time in its sole discretion:

 

(a)     The Buyer shall have executed each of
the Transaction Documents, and delivered the same to the Company.

 

(b)     The Buyer shall have delivered the
applicable Purchase Price in accordance with Section 1(b) above.

 

(c)     The Buyer shall have delivered the
original Series B Warrants to the Company.

 

(d)     The representations and warranties of
the Buyer shall be true and correct in all material respects as of the date
when made and as of the applicable Closing Date as though made at that time
(except for representations and warranties that speak as of a specific date,
which representations and warranties shall be true and correct as of such
date), and the Buyer shall have performed, satisfied and complied in all
material respects with the covenants, agreements and conditions required by
this Agreement to be performed, satisfied or complied with by the Buyer at or
prior to the Closing Date.

 

(e)     No litigation, statute, rule, regulation,
executive order, decree, ruling or injunction shall have been enacted, entered,
promulgated or endorsed by or in any court or governmental authority of
competent jurisdiction or any self-regulatory organization having authority
over the matters contemplated hereby which prohibits the consummation of any of
the transactions contemplated by this Agreement.

 

8.             CONDITIONS TO BUYER’S
OBLIGATION TO PURCHASE. The obligation of Buyer hereunder to purchase the
Note and Warrants at each Closing is subject to the satisfaction, at or before
the Closing Date, of each of the following conditions, provided that these
conditions are for such Buyer’s sole benefit and may be waived by such Buyer at
any time in its sole discretion:

 

(a)     The Company shall have executed this
Agreement and the Security Agreement, and delivered the same to the Buyer.

 

(b)     The Company shall have delivered to
such Buyer the duly executed Note and Warrants in accordance with Section 1
above.

 

(c)     The representations and warranties of
the Company contained in this Agreement, as modified by the Exhibits and
Schedules hereto, shall be true and correct in all material respects as of the
date when made and as of the Closing Date as though made at such

 

 

time (except for representations and warranties that speak as of a
specific date, which representations and warranties shall be true and correct
as of such date) and the Company shall have performed, satisfied and complied
in all material respects with the covenants, agreements and conditions required
by this Agreement to be performed, satisfied or complied with by the Company at
or prior to the Closing Date.

 

(d)     No litigation, statute, rule,
regulation, executive order, decree, ruling or injunction shall have been
enacted, entered, promulgated or endorsed by or in any court or governmental
authority of competent jurisdiction or any self-regulatory organization having
authority over the matters contemplated hereby which prohibits the consummation
of any of the transactions contemplated by this Agreement.

 

9.             GOVERNING LAW;
MISCELLANEOUS.

 

(a)     GOVERNING LAW.  The
interpretation and construction of this Agreement, and all matters relating
hereto, shall be governed by the laws of the State of New York applicable to
agreements executed and to be performed solely within such State without regard
to conflicts of laws.

 

(b)     JURISDICTION.  Any
judicial proceeding brought against any of the parties to this Agreement on any
dispute arising out of this Agreement or any matter related hereto may be
brought in the courts of the State of New York, New York County, or in the
United States District Court for the Southern District of New York, and, by
execution and delivery of this Agreement, each of the parties to this Agreement
accepts the exclusive jurisdiction of such courts, and irrevocably agrees to be
bound by any judgment rendered thereby in connection with this Agreement.  The prevailing party or parties in any such
litigation shall be entitled to receive from the losing party or parties all
costs and expenses, including reasonable counsel fees, incurred by the
prevailing party or parties.

 

(c)     COUNTERPARTS; SIGNATURES BY FACSIMILE. This Agreement may be
executed in one or more counterparts, all of which shall be considered one and
the same agreement and shall become effective when counterparts have been
signed by each party and delivered to the other party. This Agreement, once
executed by a party, may be delivered to the other party hereto by facsimile
transmission of a copy of this Agreement bearing the signature of the party so
delivering this Agreement.

 

(d)     HEADINGS. The headings of this Agreement are for convenience
of reference and shall not form part of, or affect the interpretation of, this
Agreement.

 

(e)     SEVERABILITY. If any provision of this Agreement shall be
invalid or unenforceable in any jurisdiction, such invalidity or
unenforceability shall not affect the validity or enforceability of the
remainder of this Agreement or the validity or enforceability of this Agreement
in any other jurisdiction.

 

 

(f)     ENTIRE AGREEMENT; AMENDMENTS. This Agreement and the
instruments referenced herein contain the entire understanding of the parties
with respect to the matters covered herein and therein and supersede all previous communication, representation, or Agreements
whether oral or written, between the parties with respect to the matters
covered herein. Except as
specifically set forth herein or therein, neither the Company nor the Buyer
makes any representation, warranty, covenant or undertaking with respect to
such matters.  The Agreement may not be orally modified. Only
a modification in writing, signed authorized representatives of both parties
will be enforceable.  The parties waive
the right to rely on any oral representations made by the other party, whether
in the past or in the future, regarding the subject matter of the Agreement,
the instruments referenced herein or
any other dealings between the parties related to investments or potential
investments into the Company or any securities transactions or potential
securities transactions with the Company.

 

(g)     INDEPENDENT
NATURE OF BUYERS’ OBLIGATIONS AND RIGHTS. 
The
obligations of each Buyer under any Transaction Document are several and not
joint with the obligations of any other Buyer, and no Buyer shall be
responsible in any way for the performance of the obligations of any other
Buyer under any Transaction Document. 
Nothing contained herein or in any Transaction Document, and no action
taken by any Buyer pursuant thereto, shall be deemed to constitute the Buyers
as a partnership, an association, a joint venture or any other kind of entity,
or create a presumption that the Buyers are in any way acting in concert or as
a group with respect to such obligations or the transactions contemplated by
the Transaction Documents.  Each Buyer
shall be entitled to independently protect and enforce its rights, including
without limitation, the rights arising out of this Agreement or out of the
other Transaction Documents, and it shall not be necessary for any other Buyer
to be joined as an additional party in any proceeding for such purpose.  Each Buyer has been represented by its own
separate legal counsel in their review and negotiation of the Transaction
Documents.

 

(h)     NOTICES.
Any and all notices or other communications or deliveries required or
permitted to be provided hereunder shall be in writing and shall be deemed
given and effective on the earliest of (a) the date of transmission, if
such notice or communication is delivered via facsimile at the facsimile number
set forth on the signature pages attached hereto prior to 5:30 p.m.
(New York City time) on a Trading Day, (b) the next Trading Day after the
date of transmission, if such notice or communication is delivered via
facsimile at the facsimile number set forth on the signature pages attached
hereto on a day that is not a Trading Day or later than 5:30 p.m. (New
York City time) on any Trading Day, (c) the second Trading Day following
the date of mailing, if sent by U.S. nationally recognized overnight courier
service, or (d) upon actual receipt by the party to whom such notice is
required to be given.  The address for
such notices and communications shall be as set forth on the signature pages attached
hereto.

 

(i)     SUCCESSORS AND ASSIGNS. This Agreement shall be binding upon
and inure to the benefit of the parties and their successors and assigns.
Neither the Company nor any Buyer shall assign this Agreement or any rights or
obligations hereunder without the prior written consent of the other.
Notwithstanding the foregoing, subject to Section 2(f), Buyer may assign
its rights hereunder to any person that purchases Securities in a private
transaction from a Buyer or to any of its “affiliates,” as that term is defined
under the 1934 Act, without the consent of the Company.

 

 

(j)     THIRD PARTY BENEFICIARIES. This Agreement is intended for
the benefit of the parties hereto and their respective permitted successors and
assigns, and is not for the benefit of, nor may any provision hereof be
enforced by, any other person.

 

(k)     SURVIVAL. The representations and warranties of the parties
hereto contained in this Agreement shall survive the Closing hereunder for a
period of one (1) year after each Closing contemplated by this Agreement
notwithstanding any due diligence investigation conducted by or on behalf of
the Buyer.

 

(l)     INDEMNIFICATION.  The
Company (the “INDEMNIFYING PARTY”) agrees to indemnify and hold harmless the
Buyer and all its officers, directors, employees, agents, members and managers
(the “INDEMNIFIED PARTY”) for loss or damage arising as a result of or related
to any breach or alleged breach by the Company of any of its representations,
warranties and covenants set forth in Sections 3 and 4 hereof or any of its
covenants and obligations under this Agreement, including advancement of
expenses as they are incurred with respect to claims by third parties.

 

Promptly after receipt of notice of the commencement of any action
against an Indemnified Party, such Indemnified Party shall notify the
Indemnifying Party in writing of the commencement thereof and the basis
hereunder upon which a claim for indemnification is asserted, but the failure
to do so shall not relieve the Indemnifying Party of its obligations hereunder
except to the extent the Indemnifying Party is materially prejudiced by such
failure. In the event of the commencement of any such action, the Indemnifying
Party shall be entitled to participate therein and to assume the defense thereof
with counsel satisfactory to the Indemnified Party, and, after notice from the
Indemnifying Party to the Indemnified Party of its election so to assume the
defense thereof, the Indemnifying Party shall not be liable to the Indemnified
Party hereunder for any legal expenses (including attorneys’ fees) subsequently
incurred by such Indemnified Party in connection with the defense thereof other
than reasonable costs of investigation and of liaison with counsel so selected,
provided, however, that, if the defendants in any such action include both the
Indemnified Party and the Indemnifying Party and the Indemnified Party shall
have reasonably concluded that there may be reasonable defenses available to it
which are different from or additional to those available to the Indemnifying
Party or if the interests of the Indemnified Party reasonably may be deemed to
conflict with the interests of the Indemnifying Party, the Indemnified Party
shall have the right to select one separate counsel and to assume such legal defenses
and otherwise to participate in the defense of such action, with the reasonable
expenses and fees of such separate counsel and other expenses related to such
participation to be reimbursed by the Indemnifying Party as incurred.

 

As to cases in which the Indemnifying Party has assumed and is
providing the defense for the Indemnified Party, the control of such defense
shall be vested in the Indemnifying Party; provided that the consent of the
Indemnified Party shall be required prior to any settlement of such case or
action, which consent shall not be unreasonably withheld. As to any action, the
party which is controlling such action shall provide to the other party
reasonable information (including reasonable advance notice of all proceedings
and depositions in respect thereto) regarding the conduct of the action and the
right to attend all proceedings and 

 

 

depositions in
respect thereto through its agents and attorneys, and the right to discuss the
action with counsel for the party controlling such action.

 

(m)     FURTHER ASSURANCES. Each party shall do and perform, or
cause to be done and performed, all such further acts and things, and shall
execute and deliver all such other agreements, certificates, instruments and
documents, as the other party may reasonably request in order to carry out the
intent and accomplish the purposes of this Agreement and the consummation of
the transactions contemplated hereby.

 

(n)     NO STRICT CONSTRUCTION. The language used in this Agreement
will be deemed to be the language chosen by the parties to express their mutual
intent, and no rules of strict construction will be applied against any
party.

 

(o)     REMEDIES. The Company acknowledges that a breach by it of
its obligations hereunder will cause irreparable harm to Buyer, by vitiating
the intent and purpose of the transactions contemplated hereby. Accordingly,
the Company acknowledges that the remedy at law for a breach of its obligations
under this Agreement will be inadequate and agrees, in the event of a breach or
threatened breach by the Company of the provisions of this Agreement, that
Buyer shall be entitled, in addition to all other available remedies in law or
in equity, to an injunction or injunctions to prevent or cure any breaches of
the provisions of this Agreement and to enforce specifically the terms and
provisions of this Agreement, without the necessity of showing economic loss
and without any bond or other security being required.

 

[SIGNATURE
PAGES FOLLOW]

 

 

10.          PRINCIPAL
AMOUNT AND PURCHASE PRICE.  Buyer
subscribes for a Note in the Original Principal Amount of $         (1) (“Subscription
Amount”) against payment by wire transfer in the amount of the Subscription
Amount.

 

The undersigned acknowledges that this Agreement and the subscription
represented hereby shall not be effective unless accepted by the Company as
indicated below.

 

IN WITNESS WHEREOF, the undersigned Buyer does represent and certify
under penalty of perjury that the foregoing statements are true and correct and
that Buyer by the following signature(s) executed this Agreement.

 

Dated this       day of
                          ,
            .

 

 

	
   

  	
   

  	
   

  
	
  Your Signature

  	
   

  	
  PRINT EXACT NAME IN WHICH YOU WANT

  THE SECURITIES TO BE REGISTERED

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  DELIVERY INSTRUCTIONS:

  
	
  Name: Please Print

  	
   

  	
  Please type or print address where your securities are to be
  delivered

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  ATTN.:

  	
   

  
	
  Title/Representative Capacity (if applicable)

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
  Name of Company You Represent (if applicable)

  	
   

  	
  Street Address

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
  Place of Execution of this Agreement

  	
   

  	
  City, State or Province, Country, Offshore Postal Code

  
	
   

  	
   

  	
   

  

 

 

	
   

  	
   

  
	
  Phone Number (For Federal Express) and Fax
  Number (re: Notice)

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
  WITH A COPY TO :

  	
   

  
	
  Please type or print address where copies are to be delivered

  	
   

  
	
   

  	
   

  
	
  ATTN.:

  	
   

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
  Street Address

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
  City, State or Province, Country, Offshore Postal Code

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
  Phone Number (For Federal Express) and Fax Number (re: Notice)

  	
   

  
			

 

(1) Or such lesser amount
as determined in accordance with the Confidential Offering Summary dated December 12,
2008.

 

 

THIS AGREEMENT IS ACCEPTED
BY THE COMPANY IN THE AMOUNT OF $              ON
THE        DAY OF                      ,            .

 

 

	
   

  	
  CALLISTO PHARMACEUTICALS, INC.

  
	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  By:

  	
   

  
	
   

  	
  Print Name:

  	
  Gary
  S. Jacob

  
	
   

  	
  Title:

  	
  Chief Executive Office

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00157-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00157-of-00352.parquet"}]]